SEARCH
検索詳細
久田 諒 (ヒサダ リヨウ)
| 北海道大学病院 内科 | 助教 |
| 保健センター | 助教 |
| 北海道大学病院 | 助教 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
- 00832370
研究活動情報
■ 論文- Consolidation Volume Assessed by Quantitative Computed Tomography Predicts the Prognosis of Pneumocystis Pneumonia in Rheumatic Diseases.
Kodai Sakiyama; Ryo Hisada; Mitsutaka Yasuda; Maria Tada; Yotaro Oki; Masanari Sugawara; Yuka Shimizu; Shuhei Shimoyama; Shuhei Takeyama; Tetsuya Horita; Masaru Yoshimura; Michihito Kono; Yuichiro Fujieda; Olga Amengual; Masaru Kato; Tatsuya Atsumi
Modern rheumatology, 2026年05月15日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: To investigate the prognostic value of quantitative computed tomography (QCT) analysis in pneumocystis pneumonia (PCP) patients with rheumatic diseases, specifically relating abnormal lung volumes (ALV) to major clinical events (MCE). METHODS: This multicentre, retrospective study included 83 PCP patients with rheumatic diseases. QCT automatically quantified ALV, categorised into consolidation (≥ -300 HU) and ground-glass opacities (< -300 HU). The primary outcome was MCE, including intubation, intensive care unit admission and death. Logistic regression and survival analyses assessed associations between QCT-derived volumes and MCE. RESULTS: MCE occurred in 17 patients (20%). Patients with MCE had significantly larger consolidation volumes than those without MCE (median, 5.7% vs 0.4%, p < 0.001). Logistic regression analysis identified lactate dehydrogenase, C-reactive protein, and beta-D-glucan as risk factors; however, consolidation volume remained independently associated with MCE after adjustment (odds ratio: 1.33, 95% confidence interval 1.11-1.59, p < 0.001). Receiver operating characteristic analysis of consolidation volume for predicting MCE showed an area under the curve of 0.89 (p < 0.001). Kaplan-Meier analysis revealed significantly lower MCE-free survival in patients with consolidation volumes ≥ 1.4% (p < 0.001; log-rank test). CONCLUSION: In PCP patients with rheumatic diseases, QCT-derived consolidation volume is a strong predictor of severe outcomes. - The increase of monocyte/high-density lipoprotein cholesterol ratio precedes recurrent thrombosis in patients with antiphospholipid syndrome.
Haruka Moriya; Ryo Hisada; Yuichiro Fujieda; Michihito Kono; Olga Amengual; Masaru Kato; Kazufumi Okada; Yoichi Ito; Tatsuya Atsumi
Rheumatology (Oxford, England), 2025年12月06日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: The monocyte-to-high-density lipoprotein cholesterol ratio (MHR) is an emerging biomarker associated with inflammation and oxidative stress, being linked to cardiovascular events in patients with chronic kidney disease or those with diabetes. Given that monocyte activation plays a central role in the pathogenesis of thrombosis in antiphospholipid syndrome (APS), and that HDL-cholesterol suppresses monocyte activation, we aimed to investigate whether MHR could serve as a predictor for recurrent thrombotic events in APS patients. METHODS: This retrospective longitudinal study included 107 patients diagnosed with APS at Hokkaido University Hospital. The MHR at the time of APS diagnosis was calculated and compared between patients with and without subsequent thrombotic recurrence. Among patients who experienced recurrence, MHR values were compared between two time intervals prior to the event: 0-6 months and 6-36 months. RESULTS: The median [IQR] age at diagnosis was 46 [31-56] years, with a median follow-up duration of 14.4 [11.6-17.8] years. Thrombotic events recurred in 31 patients, including 22 arterial and 9 venous events. The MHR at diagnosis did not significantly differ between patients with and without recurrence (5.0 [3.4-8.0] vs 5.3 [3.5-8.6], p = 0.57). However, among patients with recurrent thrombosis, average MHR values during the 0-6 months preceding the event were significantly higher than those measured 6-36 months prior (6.1 [4.3-8.3] vs 5.1 [3.8-8.6], p = 0.04). CONCLUSION: Our findings suggest that MHR increases in the 6 months preceding recurrent thrombotic events in APS patients, indicating that it may serve as a dynamic, time-sensitive biomarker for predicting thrombotic recurrence in thrombotic APS. - Predictive Factors for Renal Outcome During Remission Induction Treatment Period in Lupus Nephritis.
Kazuro Kamada; Michihito Kono; Shuhei Takeyama; Ryo Hisada; Yuichiro Fujieda; Masaru Kato; Olga Amengual; Tatsuya Atsumi
International journal of rheumatic diseases, 28, 11, e70470, 2025年11月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Patients with refractory lupus nephritis (LN) may benefit from the addition of anti-lupus drugs to standard remission induction therapy; however, which patients require additional treatment remains unclear. This study aimed to identify the predictive factors for renal outcomes during standard remission induction treatment for LN. METHODS: This retrospective observational study included 85 LN patients with standard remission induction therapy between 2006 and 2020. The baseline was the day of the initiation of remission induction therapy. Clinical and laboratory data were collected at 0, 2, 4, 8, 12 and 52 weeks after baseline. Complete renal remission (CRR) was defined as proteinuria < 0.5 g/gCr plus estimated glomerular filtration rate no worse than 10% below preflare value or ≥ 90 mL/min/1.73 m2 at 52 weeks. RESULTS: Among 85 patients, 48 (56.5%) achieved CRR at 52 weeks. Baseline serum creatinine (Cr) and proteinuria levels were not significantly different between the CRR and non-CRR groups. In the CRR group, the rate of decrease (%) in serum Cr at each period from baseline was significantly higher, while proteinuria at 12 weeks was significantly lower. Multivariate logistic regression identified the rate of decrease in serum Cr from baseline to 12 weeks (odds ratio = 1.25 [CI 1.03-1.55], p = 0.03) and proteinuria at 12 weeks (odds ratio = 0.71 [CI 0.49-0.95], p = 0.05) as independent predictive factors for CRR. Receiver operating characteristic curve analysis suggested proteinuria ≤ 0.8 g/gCr at 12 weeks as the best cutoff to predict CRR. CONCLUSIONS: The serum Cr decrease and proteinuria ≤ 0.8 g/gCr at 12 weeks were predictors of CRR. - Factors related to seroconversion of anti-cyclic citrullinated peptide antibody after the onset of rheumatoid arthritis: a case-control study and systematic review.
Yui Kosumi; Ryoko Asano; Aki Sugano; Masaru Yoshimura; Ryo Hisada; Michihito Kono; Yuichiro Fujieda; Tatsuya Atsumi; Masaru Kato
Immunological medicine, 1, 12, 2025年10月11日, [国際誌]
英語, 研究論文(学術雑誌), Anti-cyclic citrullinated peptide (CCP) antibodies typically present before rheumatoid arthritis (RA) but appear (seroconvert) after disease onset in some patients. This study analyzed factors related to anti-CCP seroconversion. Fifty-six consecutive patients with anti-CCP negative RA were enrolled. The first determination of anti-CCP status was defined as the baseline. Anti-CCP was then reassessed with an interval of 77 (±41) months. Demographics and baseline characteristics were compared between patients with and without anti-CCP seroconversion. Moreover, relevant studies were systematically reviewed. Six of the 56 patients experienced anti-CCP seroconversion (<4.5-12.4 [8.5-65.7] U/mL). These patients were more likely to have interstitial lung disease and HLA-DRB1 shared epitope (SE) alleles and to use biological disease-modifying antirheumatic drugs (bDMARDs). From the systematic review and meta-analysis, bDMARDs, bone erosions, HLA-DRB1 SE and rheumatoid factor positivity were identified as factors related to anti-CCP seroconversion. By selectively screening for anti-citrullinated protein antibody responses, an expansion of the repertoire was observed after the onset of RA. The seroconversion of anti-CCP after the onset of RA is associated with the typical features of RA and may therefore represent an overlooked seropositive disease. - Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Disease Activity in Patients with Rheumatoid Arthritis: A Pilot Study
Yuichiro Fujieda; Kaoru Murakami; Hiroki Tanaka; Yuichi Kojima; Yuki Kudo; Kohei Karino; Hiroyuki Nakamura; Ryo Hisada; Michihito Kono; Masaaki Murakami; Tatsuya Atsumi
ARTHRITIS & RHEUMATOLOGY, 77, 4423, 4424, 2025年10月
英語 - Right Ventricular Dysfunction in Lung Disease/Hypoxia-Associated Pulmonary Hypertension.
Hideki Shima; Ichizo Tsujino; Toshitaka Nakaya; Junichi Nakamura; Ayako Igarashi-Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Ryo Hisada; Masaru Kato; Satonori Tsuneta; Isao Yokota; Satoshi Konno
Journal of the American Heart Association, 14, 16, e042186, 2025年08月19日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Limited data exist on right ventricular (RV) function in lung disease/hypoxia-associated pulmonary hypertension (PH). We aimed to clarify the presence, characteristics, and clinical significance of RV dysfunction in patients with lung disease/hypoxia-associated PH. METHODS: We analyzed data from 3 groups of patients: those with lung disease/hypoxia-associated PH, those without PH, and those with pulmonary arterial hypertension (PAH). RV volume was assessed using cardiac magnetic resonance imaging, and RV pressure data were obtained by right heart catheterization and analyzed using dedicated software and a single-beat method. We then evaluated RV contractility by end-systolic elastance (Ees), diastolic function by β and end-diastolic elastance, and RV-pulmonary artery coupling by Ees/arterial elastance. RESULTS: We studied 68 patients with lung disease/hypoxia-associated PH, 40 without PH, and 93 with PAH. In the lung disease/hypoxia-associated PH group, Ees was sustained (0.46 [95% CI, 0.26-0.75] mm Hg/mL), whereas β (0.035 [95% CI, 0.022-0.049]) and end-diastolic elastance (0.19 [95% CI, 0.11-0.38] mm Hg/mL) were higher, and Ees/arterial elastance was lower (0.59 [95% CI, 0.27-0.79]) compared with the no-PH group. There were no differences in these values between the groups with lung disease/hypoxia-associated PH and PAH. Ees/arterial elastance was significantly correlated with the 6-minute walk distance and associated with mortality (hazard ratio, 0.18 [95% CI, 0.04-0.79]) in the group with PAH, but it was not in the group with lung disease/hypoxia-associated PH. Similarly, whereas the group with PAH showed improvement in β and Ees/arterial elastance with pulmonary vasodilator therapy, such improvement was not observed in the group with lung disease/hypoxia-associated PH. CONCLUSIONS: In lung disease/hypoxia-associated PH, RV contractility is preserved, whereas diastolic function and RV-pulmonary artery coupling are impaired. Further investigation is needed to elucidate the distinct clinical relevance of RV dysfunction in lung disease/hypoxia-associated PH. - Muscle vasculitis in patients with polymyalgia rheumatica: Three case series.
Haruka Moriya; Yuichiro Fujieda; Yuta Inoue; Kenichi Miyamoto; Mamiko Anada; Daiki Tanaka; Akihiko Kudo; Megumi Abe; Azusa Nagai; Ryo Hisada; Michihito Kono; Masaru Kato; Olga Amengual; Yoshihiro Matsuno; Ichiro Yabe; Tatsuya Atsumi
Modern rheumatology case reports, 9, 2, 1, 6, 2025年07月25日, [国際誌]
英語, 研究論文(学術雑誌), Polymyalgia rheumatica (PMR) is a common inflammatory disorder characterized by myalgia/stiffness in proximal hip and shoulder girdle, elevated C reactive protein, and erythrocyte sedimentation rate, but its pathogenesis is not fully elucidated. We report three cases of PMR who do not respond adequately to standard treatment. Those patients had typical symptoms of myalgia and muscle weakness, with elevated C reactive protein in absence of creatine kinase elevation. Muscle specimen showed the findings of vasculitis in all cases; therefore, muscular-limited vasculitis may be an underlying pathology in PMR in those refractory cases. - 若年全身性エリテマトーデス患者における睡眠健康状態と精神神経症状との関連性 PLEASURE-Jコホートを用いた検討
吉村 大; 藤枝 雄一郎; 久田 諒; 河野 通仁; 磯島 咲子; 一瀬 邦弘; 岩田 恭宜; 奥 健志; 金子 佳代子; 佐田 憲映; 田中 良哉; 藤尾 圭志; 松下 雅和; 宮前 多佳子; 村島 温子; 中島 亜矢子; 渥美 達也
日本リウマチ学会総会・学術集会プログラム・抄録集, 69回, 772, 772, (一社)日本リウマチ学会, 2025年03月
日本語 - Recent advances in immunometabolism in rheumatic diseases.
Ryo Hisada; Michihito Kono
Current opinion in rheumatology, 37, 2, 142, 148, 2025年03月01日, [国際誌]
英語, 研究論文(学術雑誌), PURPOSE OF REVIEW: Aberrant autoreactive innate and adaptive immune responses cause systemic autoimmune diseases. Autoimmunity has been linked to abnormal metabolic states, and immunometabolism has emerged as a critical field in understanding the pathogenesis of rheumatic diseases. We aimed to explore the latest research on metabolic reprogramming in various immune cell types, including T cells, B cells, neutrophils, dendritic cells, monocytes, and macrophages, in the context of rheumatic diseases. RECENT FINDINGS: Each immune cell utilizes preferred metabolic pathways, and the cell activation dramatically modifies metabolic status. The inhibition of these pathways alters cell survival, differentiation, proliferation, and cytokine production - all of which contribute to rheumatic disease progression. SUMMARY: Targeting metabolic pathways or introducing anti-inflammatory metabolites, such as itaconate, could be novel therapeutic strategies for rheumatic diseases. Further research should focus on strategies for translating basic research findings to bedside applications. - A cohort study in HigAshi-nippon of Pulmonary hyPertensIoN in systEmic SclerosiS (HAPPINESS study): protocol and baseline data for an observational study
Shuhei Takeyama; Hironari Hanaoka; Akiyoshi Hashimoto; Yusho Ishii; Yuka Shimizu; Toshiharu Takeuchi; Shuhei Shimoyama; Masataka Kuwana; Tomoaki Higuchi; Masaru Yoshimura; Hiroshi Kataoka; Yuko Shirota; Kazufumi Okada; Yoichi M. Ito; Ryo Hisada; Kazuro Kamada; Sho Ishigaki; Tetsuya Horita; Tatsuya Atsumi; Masaru Kato
BMC Rheumatology, 9, 1, Springer Science and Business Media LLC, 2025年02月26日
研究論文(学術雑誌) - Hypoxia Promotes the Expression of ADAM9 by Tubular Epithelial Cells, Which Enhances Transforming Growth Factor β1 Activation and Promotes Tissue Fibrosis in Patients With Lupus Nephritis.
Masataka Umeda; Kohei Karino; Abhigyan Satyam; Nobuya Yoshida; Ryo Hisada; Rhea Bhargava; Theodoros Vichos; Ana Laura Kunzler; Takashi Igawa; Kunihiro Ichinose; Kenta Torigoe; Tomoya Nishino; Takahiro Maeda; Caroline A Owen; Reza Abdi; Atsushi Kawakami; George C Tsokos
Arthritis & rheumatology (Hoboken, N.J.), 2024年09月15日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Enhanced expression of transforming growth factor (TGF) β in the kidneys of patients with lupus nephritis (LN) can lead to progressive fibrosis, resulting in end-organ damage. ADAM9 activates TGFβ1 by cleaving the latency-associated peptide (LAP). We hypothesized that ADAM9 in the kidney may accelerate fibrogenesis by activating TGFβ1. METHODS: We assessed the expression of ADAM9 in the kidneys of mice and humans who were lupus prone. In vitro experiments were conducted using tubular epithelial cells (TECs) isolated from mice and explored the mechanisms responsible for the up-regulation of ADAM9 and the subsequent activation of TGFβ1. To assess the role of ADAM9 in the development of tubular-intestinal fibrosis in individuals with LN, we generated MRL/lpr mice who were Adam9 deficient. RESULTS: ADAM9 was highly expressed in tubules from MRL/lpr mice. The transcription factor hypoxia-inducible factor-1α was found to promote the transcription of ADAM9 in TECs. TECs from mice who were Adam9 deficient and exposed to the hypoxia mimetic agent dimethyloxalylglycine failed to cleave the LAP to produce bioactive TGFβ1 from latent TGFβ1. Coculture of TECs from mice who were Adam9 deficient with fibroblasts in the presence of dimethyloxalylglycine and latent TGFβ1 produced decreased amounts of type I collagen and α-smooth muscle actin (SMA) by fibroblasts. MRL/lpr mice who were Adam9 deficient showed reduced interstitial fibrosis. At the translational level, ADAM9 expression in tissues and urine of patients with LN was found to increase. CONCLUSION: Hypoxia promotes the expression of ADAM9 by TECs, which is responsible for the development of interstitial fibrosis in patients with LN by enhancing the TGFβ1 activation, which promotes fibroblasts to produce collagen and α-SMA. - Phosphatidylserine-Dependent Anti-prothrombin Antibodies as a Key Predictor for Systemic Lupus Erythematosus in Patients with Primary Antiphospholipid Syndrome: A retrospective longitudinal cohort study.
Jiang Wei; Yuichiro Fujieda; Yusuke Fujita; Yusuke Ogata; Ryo Hisada; Michihito Kono; Olga Amengual; Masaru Kato; Tatsuya Atsumi
Modern rheumatology, 2024年08月27日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity. Although PAPS is distinct from systemic lupus erythematosus (SLE), the two conditions share clinical features and susceptibility genes. Progression from PAPS to SLE is well-recognized. However, risk factors for this transition are poorly understood. We aimed to identify predictors of progression to SLE in patients with PAPS. METHODS: A longitudinal single-center study was conducted at Hokkaido University Hospital from 1990 to 2021. Baseline characteristics including clinical features, laboratory data, aPL profiles were compared between patients who progressed to SLE (SLE group) and those who did not (non-SLE group). RESULTS: Among 64 patients diagnosed with PAPS at baseline, nine (13.8%) progressed to SLE over a mean follow-up of 9 years (incidence rate, 1.61 per 100 person-years). At the diagnosis of PAPS, the SLE group had a higher prevalence of anti-phosphatidylserine/prothrombin antibodies (aPS/PT) and anti-dsDNA antibodies compared to the non-SLE group. Other clinical findings, autoantibody profiles, and serum complement levels were similar between the two groups. Multivariate Cox analysis showed that IgG aPS/PT was significantly associated with SLE development (Hazard ratio: 10.3, 95% CI: 1.13-92.6, p=0.04). CONCLUSION: IgG aPS/PT may be a predictive factor for new-onset SLE in patients with PAPS, suggesting its utility in guiding risk stratification and monitoring strategies for these patients. - Relation between hydroxychloroquine dose and continuation rate in patients with systemic lupus erythematosus.
Shuhei Takeyama; Michihito Kono; Kuniyuki Aso; Kazuro Kamada; Maria Tada; Masato Tarumi; Yui Kosumi; Masaru Yoshimura; Keita Ninagawa; Ryo Hisada; Yuichiro Fujieda; Masaru Kato; Olga Amengual; Tatsuya Atsumi
Modern rheumatology, 2024年08月06日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Hydroxychloroquine (HCQ) is recommended at a target dose of 5 mg/kg per actual body weight to reduce the risk of retinopathy in systemic lupus erythematosus (SLE). However, the efficacy of HCQ has been established at doses of 6.5 mg/kg per ideal body weight. This study aimed to clarify the effects of the HCQ dose on the continuation rate in Japanese patients, who generally have a lower body mass index than Western patients. METHODS: This retrospective single-centre observational study enrolled patients with SLE on HCQ therapy. Patients were divided into two groups with a dose per actual body weight [the low-dose (<5 mg/kg) group and the high-dose (≥5 mg/kg) group], and continuation rates were compared. The efficacy of 1-year HCQ therapy was assessed in patients without additional immunosuppressive agents and biologics. RESULTS: Of the 231 patients enrolled, 48 (20.8%) discontinued HCQ. The HCQ dose per actual body weight was identified as an independent risk factor for discontinuation. The low-dose group showed a significantly higher 1-year HCQ continuation rate than the high-dose group (83.2% vs. 72.8%, respectively). Both groups showed reductions in glucocorticoid requirement and serological activity after 1-year HCQ therapy. CONCLUSIONS: HCQ <5 mg/kg per actual body weight may facilitate greater continuation. - Potential therapies targeting metabolic pathways in systemic lupus erythematosus.
Ryo Hisada; Michihito Kono
Clinical immunology (Orlando, Fla.), 263, 110224, 110224, 2024年06月, [国際誌]
英語, 研究論文(学術雑誌), The pathophysiology of systemic lupus erythematosus (SLE) is multifactorial and involves alterations in metabolic pathways, including glycolysis, lipid metabolism, amino acid metabolism, and mitochondrial dysfunction. Increased glycolysis in SLE T cells, which is associated with elevated glucose transporter 1 expression, suggests targeting glucose transporters and hexokinase as potential treatments. Abnormalities in lipid metabolism, particularly in lipid rafts and enzymes, present new therapeutic targets. This review discusses how changes in glutaminolysis and tryptophan metabolism affect T-cell function, suggesting new therapeutic interventions, as well as mitochondrial dysfunction in SLE, which increases reactive oxygen species. The review also emphasizes that modulating metabolic pathways in immune cells is a promising approach for SLE treatment, and can facilitate personalized therapies based on individual metabolic profiles of patients with SLE. The review provides novel insights into strategies for managing SLE. - Itaconate reduces proliferation and migration of fibroblast-like synoviocytes and ameliorates arthritis models.
Maria Tada; Yuki Kudo; Michihito Kono; Masatoshi Kanda; Shuhei Takeyama; Kodai Sakiyama; Hotaka Ishizu; Tomohiro Shimizu; Tsutomu Endo; Ryo Hisada; Yuichiro Fujieda; Masaru Kato; Olga Amengual; Norimasa Iwasaki; Tatsuya Atsumi
Clinical immunology (Orlando, Fla.), 264, 110255, 110255, 2024年05月18日, [国際誌]
英語, 研究論文(学術雑誌), Fibroblast-like synoviocytes (FLS) play critical roles in rheumatoid arthritis (RA). Itaconate (ITA), an endogenous metabolite derived from the tricarboxylic acid (TCA) cycle, has attracted attention because of its anti-inflammatory, antiviral, and antimicrobial effects. This study evaluated the effect of ITA on FLS and its potential to treat RA. ITA significantly decreased FLS proliferation and migration in vitro, as well as mitochondrial oxidative phosphorylation and glycolysis measured by an extracellular flux analyzer. ITA accumulates metabolites including succinate and citrate in the TCA cycle. In rats with type II collagen-induced arthritis (CIA), intra-articular injection of ITA reduced arthritis and bone erosion. Irg1-deficient mice lacking the ability to produce ITA had more severe arthritis than control mice in the collagen antibody-induced arthritis. ITA ameliorated CIA by inhibiting FLS proliferation and migration. Thus, ITA may be a novel therapeutic agent for RA. - The chest CT signs for pulmonary veno-occlusive disease correlate with pulmonary haemodynamics in systemic sclerosis.
Haruka Moriya; Masaru Kato; Ryo Hisada; Keita Ninagawa; Maria Tada; Kodai Sakiyama; Mitsutaka Yasuda; Michihito Kono; Yuichiro Fujieda; Olga Amengual; Yasuka Kikuchi; Ichizo Tsujino; Takahiro Sato; Tatsuya Atsumi
Rheumatology (Oxford, England), 2023年09月15日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc) sometimes accompanies pulmonary veno-occlusive disease (PVOD). We aimed to reveal the relation between clinical signs of PVOD and severing of pulmonary vasculopathy in SSc. METHODS: This study comprised 52 consecutive SSc patients who had pulmonary haemodynamic abnormalities (mPAP > 20 mmHg, PVR > 2 W.U. or PAWP > 15 mmHg). The chest CT scan was evaluated in all patients. Patients were divided into two groups, the 0-1 group and the 2-3 group, according to the number of chest CT signs for PVOD, including 1) mediastinal lymph node enlargement, 2) thickened interlobular septal wall, and 3) ground glass opacity. Pulmonary haemodynamics, echocardiography and MRI-based cardiac function, pulmonary function, and serum biomarkers were compared between the two groups. RESULTS: Mediastinal lymph node enlargement, thickened interlobular septal wall, and ground glass opacity were observed in 11 (21%), 32 (62%), and 11 (21%) patients, respectively. The 2-3 group (n = 15) had higher mPAP (p= 0.02) while lower DLco/VA (p= 0.02) compared with the 0-1 group (n = 37). Other parameters, including PAWP, cardiac output, left ventricular ejection fraction, left atrial diameter, forced vital capacity, brain natriuretic peptide, and Krebs von den Lunge-6 were not different between the two groups. CONCLUSION: The CT signs for PVOD had positive correlation with mPAP but negative correlation with DLco in SSc patients, indicating that PAH-SSc may reflect a spectrum of pulmonary vascular disease that ranges from the pulmonary artery to the vein. - Clinical and Hemodynamic Responses to Imatinib in Pulmonary Veno-Occlusive Disease/Pulmonary Capillary Hemangiomatosis: A Retrospective Pilot Study of Five Cases and Review of the Literature
Junichi Nakamura; Ichizo Tsujino; Hideki Shima; Toshitaka Nakaya; Ayako Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Satonori Tsuneta; Ryo Hisada; Masaru Kato; Satoshi Konno
American Journal of Cardiovascular Drugs, 23, 3, 329, 338, Springer Science and Business Media LLC, 2023年03月30日
研究論文(学術雑誌) - Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease.
Maria Tada; Shion Kachi; Masahiro Onozawa; Yuichiro Fujieda; Shota Yoshida; Yotaro Oki; Kazuro Kamada; Jun Nagai; Satomi Okada; Ryo Kikuchi; Ryo Hisada; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Shinichi Nakazato; Yoshihiro Matsuno; Takanori Teshima; Tatsuya Atsumi
Internal medicine (Tokyo, Japan), 2023年03月15日, [国内誌]
英語, 研究論文(学術雑誌), We herein report a case of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) resembling adult-onset Still's disease (AOSD). A 40-year-old woman presented with a fever, erythema, and painful subcutaneous nodules on the trunk. Laboratory data and a bone marrow analysis showed hemophagocytic syndrome. Although AOSD was suspected, based on a histopathological evaluation of the erythema, she was diagnosed with SPTCL. She was refractory to combination chemotherapy but achieved durable remission with cyclosporine monotherapy. Genetic testing revealed a homozygous HAVCR2 c.245A>G variant (rs184868814) that had caused NLRP3 inflammasome activation. SPTCL and AOSD share a pathogenesis in terms of NLRP3 inflammasome activation, so the clinical phenotype of SPTCL reasonably mimics AOSD. - Itaconate ameliorates autoimmunity by modulating T cell imbalance via metabolic and epigenetic reprogramming
Kuniyuki Aso; Michihito Kono; Masatoshi Kanda; Yuki Kudo; Kodai Sakiyama; Ryo Hisada; Kohei Karino; Yusho Ueda; Daigo Nakazawa; Yuichiro Fujieda; Masaru Kato; Olga Amengual; Tatsuya Atsumi
Nature Communications, 14, 1, Springer Science and Business Media LLC, 2023年02月27日
研究論文(学術雑誌), Abstract
Dysregulation of Th17 and Treg cells contributes to the pathophysiology of many autoimmune diseases. Herein, we show that itaconate, an immunomodulatory metabolite, inhibits Th17 cell differentiation and promotes Treg cell differentiation by orchestrating metabolic and epigenetic reprogramming. Mechanistically, itaconate suppresses glycolysis and oxidative phosphorylation in Th17- and Treg-polarizing T cells. Following treatment with itaconate, the S-adenosyl-L-methionine/S-adenosylhomocysteine ratio and 2-hydroxyglutarate levels are decreased by inhibiting the synthetic enzyme activities in Th17 and Treg cells, respectively. Consequently, these metabolic changes are associated with altered chromatin accessibility of essential transcription factors and key gene expression in Th17 and Treg cell differentiation, including decreased RORγt binding at the Il17a promoter. The adoptive transfer of itaconate-treated Th17-polarizing T cells ameliorates experimental autoimmune encephalomyelitis. These results indicate that itaconate is a crucial metabolic regulator for Th17/Treg cell balance and could be a potential therapeutic agent for autoimmune diseases. - Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study.
Keita Ninagawa; Masaru Kato; Satonori Tsuneta; Suguru Ishizaka; Hideyuki Ujiie; Ryo Hisada; Michihito Kono; Yuichiro Fujieda; Yoichi M Ito; Tatsuya Atsumi
Rheumatology (Oxford, England), 62, 7, 2550, 2555, 2022年12月02日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Nintedanib is an inhibitor of tyrosine kinases that has been shown to slow the progression of interstitial lung disease (ILD), including ILD associated with systemic sclerosis (SSc). The aim of this study was to explore the effect of nintedanib on cardiomyopathy associated with SSc. METHODS: Twenty consecutively hospitalized patients with SSc-ILD were enrolled and prospectively followed. The rate of change at six months in cardiac magnetic resonance (CMR) parametric mapping, including myocardial extracellular volume, was primarily evaluated. Other endpoints included changes in CMR functional parameters, echocardiographic parameters, modified Rodnan skin score, serum biomarkers, and pulmonary function test. RESULTS: Nintedanib was administered in 10 patients, whereas the other 10 were treated without nintedanib or watched, according to ILD severity and progression. Baseline values of CMR parametric mapping were not different between the two groups. The rate of change at six months in myocardial extracellular volume was largely different, almost divergent between the nintedanib group and the control group (-1.62% vs. +2.00%, p= 0.0001). Among other endpoints, the change in right ventricular ejection fraction was significantly different between the two groups (p= 0.02), with a preferential change in the nintedanib group. CONCLUSION: Our data indicate beneficial signals of nintedanib on cardiomyopathy associated with SSc. The anti-fibrotic effect of nintedanib might not be limited to the lung. - Phosphofructokinase P fine-tunes T regulatory cell metabolism, function, and stability in systemic autoimmunity.
Marc Scherlinger; Wenliang Pan; Ryo Hisada; Afroditi Boulougoura; Nobuya Yoshida; Milena Vukelic; Masataka Umeda; Suzanne Krishfield; Maria G Tsokos; George C Tsokos
Science advances, 8, 48, eadc9657, 2022年12月02日, [国際誌]
英語, 研究論文(学術雑誌), Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by defective regulatory T (Treg) cells. Here, we demonstrate that a T cell-specific deletion of calcium/calmodulin-dependent protein kinase 4 (CaMK4) improves disease in B6.lpr lupus-prone mice and expands Treg cells. Mechanistically, CaMK4 phosphorylates the glycolysis rate-limiting enzyme 6-phosphofructokinase, platelet type (PFKP) and promotes aerobic glycolysis, while its end product fructose-1,6-biphosphate suppresses oxidative metabolism. In Treg cells, a CRISPR-Cas9-enabled Pfkp deletion recapitulated the metabolism of Camk4-/- Treg cells and improved their function and stability in vitro and in vivo. In SLE CD4+ T cells, PFKP enzymatic activity correlated with SLE disease activity and pharmacologic inhibition of CaMK4-normalized PFKP activity, leading to enhanced Treg cell function. In conclusion, we provide molecular insights in the defective metabolism and function of Treg cells in SLE and identify PFKP as a target to fine-tune Treg cell metabolism and thereby restore their function. - Efficacy and safety of oral pulmonary vasodilators in pulmonary veno‐occlusive disease
Junichi Nakamura; Ichizo Tsujino; Hideki Shima; Toshitaka Nakaya; Ayako Sugimoto; Takahiro Sato; Taku Watanabe; Hiroshi Ohira; Masaru Suzuki; Satonori Tsuneta; Ryo Hisada; Masaru Kato; Satoshi Konno
Pulmonary Circulation, 12, 4, Wiley, 2022年10月
研究論文(学術雑誌) - Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin-2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus.
Ryo Hisada; Nobuya Yoshida; Seo Yeon K Orite; Masataka Umeda; Catalina Burbano; Marc Scherlinger; Michihito Kono; Suzanne Krishfield; George C Tsokos
Arthritis & rheumatology (Hoboken, N.J.), 74, 7, 1204, 1210, 2022年07月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Glutaminase (GLS) isoenzymes GLS1 and GLS2 catalyze the first step of glutaminolysis. GLS1 is requisite for Th17 cell differentiation, and its inhibition suppresses autoimmune disease in animals, but the function of GLS2 is not known. The aim of this study was to investigate the role of GLS2 in CD4+ T cell function and systemic lupus erythematosus (SLE) pathogenesis. METHODS: We measured reactive oxygen species (ROS) levels, lipid peroxidation, and mitochondrial mass and polarization by flow cytometry, interleukin-2 (IL-2) production by a dual luciferase assay, and CpG DNA methylation of Il2 by a real-time polymerase chain reaction system. The impact of the overexpression of wild-type GLS1, wild-type GLS2, or mutated GLS2 at the PDZ domain-binding motif in CD4+ T cells was examined. Furthermore, GLS2 expression in CD4+ T cells from lupus-prone mice and patients with SLE was analyzed by Western blotting. RESULTS: GLS2, but not GLS1, reduced ROS levels and lipid peroxidation and restored mitochondrial function in T cells. GLS2 promoted IL-2 production through the demethylation of the Il2 promoter. Mutation of the PDZ domain-binding motif abated the ability of GLS2 to regulate IL-2 and ROS levels. In lupus-prone mice and patients with SLE, the expression of GLS2 was decreased in CD4+ T cells. Finally, GLS2 overexpression corrected ROS levels and restored IL-2 production by CD4+ T cells from lupus-prone mice and SLE patients. CONCLUSION: Our findings suggest that GLS2 has a crucial role in IL-2 production by CD4+ T cells by supporting antioxidant defense, and they offer a new approach to correcting IL-2 production by T cells in SLE. - Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.
Abhigyan Satyam; Ryo Hisada; Rhea Bhargava; Maria G Tsokos; George C Tsokos
Translational research : the journal of laboratory and clinical medicine, 245, 18, 29, 2022年07月, [国際誌]
英語, 研究論文(学術雑誌), The complement system is involved in the origin of autoimmunity and systemic lupus erythematosus. Both genetic deficiency of complement components and excessive activation are involved in primary and secondary renal diseases, including lupus nephritis. Among the pathways, the classical pathway has long been accepted as the main pathway of complement activation in systemic lupus erythematosus. However, more recent studies have shown the contribution of factors B and D which implies the involvement of the alternative pathway. While there is evidence on the role of the lectin pathway in systemic lupus erythematosus, it is yet to be demonstrated whether this pathway is protective or harmful in lupus nephritis. Complement is being explored for the development of disease biomarkers and therapeutic targeting. In the current review we discuss the involvement of complement in lupus nephritis. - The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription.
Ryo Hisada; Nobuya Yoshida; Masataka Umeda; Catalina Burbano; Rhea Bhargava; Marc Scherlinger; Michihito Kono; Vasileios C Kyttaris; Suzanne Krishfield; George C Tsokos
Cellular & molecular immunology, 19, 6, 738, 750, 2022年06月, [国際誌]
英語, 研究論文(学術雑誌), Aberrant IL-17A expression together with reduced IL-2 production by effector CD4+ T cells contributes to the pathogenesis of systemic lupus erythematosus (SLE). Here, we report that Sirtuin 2 (SIRT2), a member of the family of NAD+-dependent histone deacetylases, suppresses IL-2 production by CD4+ T cells while promoting their differentiation into Th17 cells. Mechanistically, we show that SIRT2 is responsible for the deacetylation of p70S6K, activation of the mTORC1/HIF-1α/RORγt pathway and induction of Th17-cell differentiation. Additionally, SIRT2 was shown to be responsible for the deacetylation of c-Jun and histones at the Il-2 gene, resulting in decreased IL-2 production. We found that the transcription factor inducible cAMP early repressor (ICER), which is overexpressed in T cells from people with SLE and lupus-prone mice, bound directly to the Sirt2 promoter and promoted its transcription. AK-7, a SIRT2 inhibitor, limited the ability of adoptively transferred antigen-specific CD4+ T cells to cause autoimmune encephalomyelitis in mice and limited disease in lupus-prone MRL/lpr mice. Finally, CD4+ T cells from SLE patients exhibited increased expression of SIRT2, and pharmacological inhibition of SIRT2 in primary CD4+ T cells from patients with SLE attenuated the ability of these cells to differentiate into Th17 cells and promoted the generation of IL-2-producing T cells. Collectively, these results suggest that SIRT2-mediated deacetylation is essential in the aberrant expression of IL-17A and IL-2 and that SIRT2 may be a promising molecular target for new SLE therapies. - Novel susceptibility loci for steroid-associated osteonecrosis of the femoral head in systemic lupus erythematosus.
Hiroyuki Suetsugu; Kwangwoo Kim; Takuaki Yamamoto; So-Young Bang; Yuma Sakamoto; Jung-Min Shin; Nobuhiko Sugano; Ji Soong Kim; Masaya Mukai; Yeon-Kyung Lee; Koichiro Ohmura; Dae Jin Park; Daisuke Takahashi; Ga-Young Ahn; Kohei Karino; Young-Chang Kwon; Tomoya Miyamura; Jihye Kim; Junichi Nakamura; Goro Motomura; Takeshi Kuroda; Hiroaki Niiro; Takeshi Miyamoto; Tsutomu Takeuchi; Katsunori Ikari; Koichi Amano; Yoshifumi Tada; Ken Yamaji; Masato Shimizu; Takashi Atsumi; Taisuke Seki; Yoshiya Tanaka; Toshikazu Kubo; Ryo Hisada; Tomokazu Yoshioka; Mihoko Yamazaki; Tamon Kabata; Tomomichi Kajino; Yoichi Ohta; Takahiro Okawa; Yohei Naito; Ayumi Kaneuji; Yuji Yasunaga; Kenji Ohzono; Kohei Tomizuka; Masaru Koido; Koichi Matsuda; Yukinori Okada; Akari Suzuki; Bong-Jo Kim; Yuta Kochi; Hye-Soon Lee; Shiro Ikegawa; Sang-Cheol Bae; Chikashi Terao
Human molecular genetics, 31, 7, 1082, 1095, 2022年03月31日, [国際誌]
英語, 研究論文(学術雑誌), Osteonecrosis of the femoral head (ONFH) involves necrosis of bone and bone marrow of the femoral head caused by ischemia with unknown etiology. Previous genetic studies on ONFH failed to produce consistent results, presumably because ONFH has various causes with different genetic backgrounds and the underlying diseases confounded the associations. Steroid-associated ONFH (S-ONFH) accounts for one-half of all ONFH, and systemic lupus erythematosus (SLE) is a representative disease underlying S-ONFH. We performed a genome-wide association study (GWAS) to identify genetic risk factors for S-ONFH in patients with SLE. We conducted a two-staged GWAS on 636 SLE patients with S-ONFH and 95 588 non-SLE controls. Among the novel loci identified, we determined S-ONFH-specific loci by comparing allele frequencies between SLE patients without S-ONFH and non-SLE controls. We also used Korean datasets comprising 148 S-ONFH cases and 37 015 controls to assess overall significance. We evaluated the functional annotations of significant variants by in silico analyses. The Japanese GWAS identified 4 significant loci together with 12 known SLE susceptibility loci. The four significant variants showed comparable effect sizes on S-ONFH compared with SLE controls and non-SLE controls. Three of the four loci, MIR4293/MIR1265 [odds ratio (OR) = 1.99, P-value = 1.1 × 10-9)], TRIM49/NAALAD2 (OR = 1.65, P-value = 4.8 × 10-8) and MYO16 (OR = 3.91, P-value = 4.9 × 10-10), showed significant associations in the meta-analysis with Korean datasets. Bioinformatics analyses identified MIR4293, NAALAD2 and MYO16 as candidate causal genes. MIR4293 regulates a PPARG-related adipogenesis pathway relevant to S-ONFH. We identified three novel susceptibility loci for S-ONFH in SLE. - ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-β1.
Masataka Umeda; Nobuya Yoshida; Ryo Hisada; Catalina Burbano; Seo Yeon K Orite; Michihito Kono; Vasileios C Kyttaris; Suzanne Krishfield; Caroline A Owen; George C Tsokos
Proceedings of the National Academy of Sciences of the United States of America, 118, 18, 2021年05月04日, [国際誌]
英語, 研究論文(学術雑誌), The a disintegrin and metalloproteinase (ADAM) family of proteinases alter the extracellular environment and are involved in the development of T cells and autoimmunity. The role of ADAM family members in Th17 cell differentiation is unknown. We identified ADAM9 to be specifically expressed and to promote Th17 differentiation. Mechanistically, we found that ADAM9 cleaved the latency-associated peptide to produce bioactive transforming growth factor β1, which promoted SMAD2/3 phosphorylation and activation. A transcription factor inducible cAMP early repressor was found to bind directly to the ADAM9 promoter and to promote its transcription. Adam9-deficient mice displayed mitigated experimental autoimmune encephalomyelitis, and transfer of Adam9-deficient myelin oligodendrocyte globulin-specific T cells into Rag1 -/- mice failed to induce disease. At the translational level, an increased abundance of ADAM9 levels was observed in CD4+ T cells from patients with systemic lupus erythematosus, and ADAM9 gene deletion in lupus primary CD4+ T cells clearly attenuated their ability to differentiate into Th17 cells. These findings revealed that ADAM9 as a proteinase provides Th17 cells with an ability to activate transforming growth factor β1 and accelerates its differentiation, resulting in aberrant autoimmunity. - Incidence and risk of antiresorptive agent-related osteonecrosis of the jaw (ARONJ) after tooth extraction in patients with autoimmune disease.
Yuichiro Fujieda; Mototsugu Doi; Takuya Asaka; Masahiro Ota; Ryo Hisada; Naoki Ohnishi; Michihiro Kono; Hiraku Kameda; Daigo Nakazawa; Masaru Kato; Olga Amengual; Masahiko Takahata; Shinsuke Yasuda; Yoshimasa Kitagawa; Tatsuya Atsumi
Journal of bone and mineral metabolism, 38, 4, 581, 588, 2020年07月, [国内誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Antiresorptive agent-related osteonecrosis of the jaw (ARONJ) is a rare but serious complication in patients receiving antiresorprtive agents (AR). However, the incidence of ARONJ after tooth extraction in patients with autoimmune disease (AID) remains unclear. The present study aimed to clarify the high-risk population of ARONJ in patients with AID. MATERIALS AND METHODS: The study population comprised 232 patients treated with AR, AID or non-AID, who had undergone dental extraction from January 2011 to September 2017. The incidence and risk factors of ARONJ were analysed retrospectively. Additionally, the relationship between ARONJ and osteoporotic fracture (OF) and AR discontinuation during dental procedures was investigated. RESULTS: Of 232 patients, 10 developed ARONJ within 1 year of dental extraction. The incidence of ARONJ in patients with AID was higher than that in non-AID patients (2.0/100 person-year vs 0.5/100 person-year; p = 0.03). Among the AID patients, RA patients had strikingly high incidence of ARONJ (3.6/100 person-year). The incidence of neither ARONJ nor OF significantly differed between patients who continued and discontinued AR in the perioperative period. CONCLUSION: Patients with AID who undergo dental extraction are at high risk of ARONJ. Discontinuation of AR would not significantly contribute to reduce the incidence of ARONJ in those patients. - Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts.
Eri Sugawara; Masaru Kato; Yuki Kudo; Wenshi Lee; Ryo Hisada; Yuichiro Fujieda; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Shinsuke Yasuda; Tomohiro Onodera; Shigetsugu Hatakeyama; Tatsuya Atsumi
Autophagy, 16, 5, 946, 955, 2020年05月, [国際誌]
英語, 研究論文(学術雑誌), We aimed to investigate the involvement of macroautophagy/autophagy in autoimmunity in rheumatoid arthritis (RA) through citrullination of VIM (vimentin) and its interaction with MHC class II in synovial fibroblasts (SFs). The cell surface expression of MHC class II and B7 costimulatory molecules on SFs was analyzed by flow cytometry after treatment with IFNG/IFN-γ (interferon gamma). Intracellular citrullinated autoantigens in SFs were analyzed by immunoblotting using serum from anti-citrullinated peptide antibodies (ACPA)-positive patient as a primary antibody. SFs were incubated in serum-free medium or treated with proteasome inhibitor MG132 to induce autophagy. An autophagy inhibitor 3-methyladenin (3-MA) was used. Intracellular citrullinated VIM (cVIM) was evaluated by immunoblotting and immunocytochemistry. The interaction between MHC class II and cVIM was evaluated with co-immunoprecipitation and proximity ligation assay (PLA). We demonstrated that MHC class II, CD274/B7-H1 and PDCD1LG2/B7-DC were expressed on SFs following treatment with IFNG whereas CD276/B7-H3 was detected on SFs regardless of the presence of IFNG. ACPA-positive sera recognized a 54 kDa protein in SFs. By immunoprecipitation, the 54 kDa protein recognized by RA sera was revealed to be cVIM. Following induction of autophagy, intracellular cVIM was increased in SFs but the effect was canceled by 3-MA. The interaction between MHC class II and cVIM was demonstrated by co-immunoprecipitation. Furthermore, PLA revealed the significant increase of MHC class II-cVIM interaction following induction of autophagy. Our findings suggest that SFs may contribute to the autoimmunity in RA through citrullination of VIM and its interaction with MHC class II promoted by autophagy.Abbreviations: 3-MA: 3-methyladenine; ACPA: anti-citrullinated peptide antibodies; anti-CCP: anti-cyclic citrullinated peptide antibody; cVIM: citrullinated VIM; BECN1: beclin1; DAPI: 4',6-diamidino-2-phenylindole; FBS: fetal bovine serum; HLA: human leukocyte antigen; IFNG/IFN-γ: interferon gamma; IL6: interleukin 6; IP: immunoprecipitation; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MFI: mean fluorescence index; MHC: major histocompatibility complex; OA: osteoarthritis; PADI: peptidyl arginine deiminase; PepA: pepstatin A; PBS: phosphate-buffered saline; PtdIns3K: phosphatidylinositol 3-kinase; RA: rheumatoid arthritis; SFs: synovial fibroblasts; siRNA: small interfering RNA; VIM: vimentin. - Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot study.
Atsushi Noguchi; Shinsuke Yasuda; Ryo Hisada; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Miho Suzuki; Yoshihiro Matsumoto; Tatsuya Atsumi
Modern rheumatology, 30, 2, 276, 281, 2020年03月, [国際誌]
英語, 研究論文(学術雑誌), Objectives: To analyze the effects of tocilizumab on peripheral B-cell subpopulation and its ability to produce anti-cyclic citrullinated peptide (CCP) antibody in patients with rheumatoid arthritis (RA).Methods: Thirteen consecutive RA patients initiated with tocilizumab were enrolled in our prospective study. Anti-CCP antibody titers and clinical parameters were evaluated during treatment. Peripheral blood B-cell subsets were analyzed using flow cytometry according to the Human Immunology Project.Results: Disease activity was significantly improved and anti-CCP antibody titers significantly decreased at week 24 compared to baseline. The percentages of post-switch memory B cells in CD19+ cells transiently increased at week 12, but there was no significant difference in any of the investigated B-cell subpopulations at week 24 compared to baseline. The ratios of post-switch memory to naïve B cells (post-switch/naïve) correlated negatively with anti-CCP antibody titers regardless of the time-points.Conclusion: Our study indicated that tocilizumab has a potential to reduce anti-CCP antibody production presumably by affecting post-switch/naïve ratio, and that anti-CCP antibody titers reflect B-cell distribution/subpopulation. As anti-CCP antibodies are produced in lymph nodes or ectopic lymphoid structures in synovial tissues, not in circulation, transient increment of post-switch memory B cells after tocilizumab treatment may reflect the altered balance of B-cell distribution between circulation and arthritic joints, resulting in suppressed production of anti-CCP antibody in situ. - Calcineurin inhibitors for adult-onset Still's disease: a multicentre retrospective cohort study.
Hiroyuki Nakamura; Yuichiro Fujieda; Masato Tarumi; Hirohiko Kitakawa; Ryo Hisada; Ikuma Nakagawa; Atsushi Noguchi; Takashi Kurita; Hiroshi Kataoka; Hideki Kasahara; Yoshiharu Amasaki; Isao Yokota; Tatsuya Atsumi
Clinical and experimental rheumatology, 2020年02月19日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: To clarify the efficacy and safety of calcineurin inhibitors (CNI) for treating adult-onset Still's disease (AOSD). METHODS: This multicentre historical cohort study enrolled the consecutive patients with AOSD according to Yamaguchi classification criteria. The endpoints were set as the time from the initiation of treatment to events, the persistency rate of CNI and safety. Based on the recurrent event data analysis, these endpoints were evaluated for each event. We divided the events into two groups according to the treatment that included CNI or conventional therapy without CNI. RESULTS: One hundred seventy-eight patients with 247 events were analysed. CNI were predominantly used in 72 events with a recurrent history, typical skin rash, high ferritin levels, and/or severe complications such as macrophage activation syndrome, disseminated intravascular coagulation, serositis, meningitis. CNI led to a significantly longer event-free survival (hazard ratio: 0.57, 95% confidential interval: 0.32-0.99) after adjustment of concomitant medications. Subgroup analysis showed that CNI were effective for AOSD patients with high ALT level (hazard ratio: 0.11, 95% confidential interval: 0.02-0.59) and severe complications (hazard ratio: 0.11, 95% confidential interval: 0.01-0.94). The persistency rate of CNI was 71% at 5th year. Adverse events occurred more frequently in the CNI group (18% versus 8%, p=0.02); however, CNI did not involve in increased risk of adverse events, including nephrotoxicity, after adjustment (p=0.23). CONCLUSIONS: Our retrospective analysis suggested that CNI could be an effective and safe option for treating AOSD. - Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation.
Ryo Hisada; Masaru Kato; Eri Sugawara; Masatoshi Kanda; Yuichiro Fujieda; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Journal of thrombosis and haemostasis : JTH, 17, 7, 1134, 1143, 2019年07月, [国際誌]
英語, 研究論文(学術雑誌), Essentials The mechanism of antiphospholipid antibodies (aPL) production remains unclear. We investigated lymphocyte subset, single nucleotide polymorphisms (SNP), and aPL-producing cells. The increase of circulating plasmablasts was associated with type I interferon upregulation. Our novel ex vivo assay revealed circulating plasmablasts as a major source of aPL. SUMMARY: Background/objective Antiphospholipid antibodies (aPL) are pathogenic autoantibodies in antiphospholipid syndrome (APS). This study aimed to clarify the mechanism of aPL production. Methods T cell and B cell subsets were evaluated in peripheral blood mononuclear cells (PBMCs) of 26 primary APS (PAPS), 19 systemic lupus erythematosus-associated APS (SLE/APS) patients and 10 healthy controls. The SLE-related or APS-related single nucleotide polymorphisms (SNP) were analyzed in those patients. Interferon (IFN) score was calculated based on the mRNA expression of Ly6e, Mx1, IFIT1, and IFIT3 in PBMCs. The PBMCs obtained from APS patients were cultured ex vivo following depletion of CD20 positive or negative B cells and the culture supernatants were applied to aPL measurements. Results In PAPS and SLE/APS patients, Th2, Th17, and plasmablasts were increased while regulatory T, memory B, and regulatory B cells were decreased compared to healthy controls. Genetic analysis revealed that the increase of plasmablasts was more pronounced in patients carrying a risk allele of toll like receptor (TLR) 7 SNP rs3853839. The IFN score was significantly higher in the risk allele carriers. Ex vivo experiments showed that aPL were present in the culture supernatant of PBMCs lacking CD20+CD19+ subset, but not in that of cells lacking CD20-CD19+ subset. Conclusions Our data indicate an important role of plasmablasts in the production of aPL. Furthermore, the increase of plasmablasts was associated with TLR 7 and type I IFN, suggesting a common pathophysiology in SLE and APS. Targeting plasmablasts might be a novel immunological therapeutic approach in the treatment of APS. - Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndrome.
Naoki Ohnishi; Yuichiro Fujieda; Ryo Hisada; Hiroyuki Nakamura; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Shinsuke Yasuda; Tatsuya Atsumi
Rheumatology (Oxford, England), 58, 6, 969, 974, 2019年06月01日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Warfarin is regarded as the standard treatment for preventing thrombotic events in APS, but the recurrence rate is still high. Dual antiplatelet therapy (DAPT) has been shown to be effective for the prevention of acute coronary syndrome or stroke. The objective of this study was to evaluate the efficacy of DAPT for the prevention of thrombosis recurrence in APS patients with history of arterial thrombosis. METHODS: This retrospective cohort study of APS patients was conducted at Hokkaido University Hospital between 1990 and 2016. The secondary prophylactic effects and safety of warfarin monotherapy (Wf), antiplatelet monotherapy (AP), warfarin and antiplatelet combination therapy (Wf + AP) and DAPT were evaluated. The primary endpoints were set as thrombosis-free and adverse events-free survival period. Adverse events were defined as severe bleeding and death. RESULTS: A total of 90 APS patients were enrolled. Thrombotic recurrence was found in 40 patients (35 arterial and 5 venous thromboses) and serious adverse events in 20 patients (9 severe bleeding events and 14 deaths). Kaplan-Meier analysis demonstrated a 10-year recurrence-free survival rate of 62%. The recurrence rate per 100 patient-years was as follows: Wf: 11.6, AP: 5.5, Wf: + AP: 3.7, DAPT: 1.8. We demonstrated that DAPT significantly reduced the rate of recurrence compared with Wf (log-rank P = 0.001). There were no significant differences in the rate of serious adverse events among the groups. CONCLUSION: DAPT might be considered as an effective and safe option for the prophylaxis of recurrent arterial thrombosis in APS. - Pathogenic roles of anti-C1q antibodies in recurrent pregnancy loss.
Kazumasa Ohmura; Kenji Oku; Tamao Kitaori; Olga Amengual; Ryo Hisada; Masatoshi Kanda; Yuka Shimizu; Yuichiro Fujieda; Masaru Kato; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Mayumi Sugiura-Ogasawara; Tatsuya Atsumi
Clinical immunology (Orlando, Fla.), 203, 37, 44, 2019年06月, [国際誌]
英語, 研究論文(学術雑誌), Recurrent pregnancy loss (RPL) is often considered idiopathic, however excessive complement activation has been observed in pregnancy related manifestations. Anti-C1q antibodies (anti-C1q) are associated with the activation of complement pathway in lupus patients, while it remains unclear in RPL. Firstly, we showed that both the prevalence and titre of anti-C1q were significantly higher in unexplained RPL than in healthy parous individuals. Secondly, we established the murine model of anti-C1q induced pregnancy loss using a monoclonal anti-mouse C1q antibody, JL-1. In mice treated with JL-1, high ratio of pregnancy loss and fetal growth restriction were frequently observed and complement activation occurred. C5a receptor (C5aR) blockade cancelled these pathogenic changes in mice treated with JL-1. In conclusion, our study reveals an association between the prevalence of anti-C1q and RPL. Additionally, our murine model has indicated that anti-C1q can induce reproductive failure, which might be ameliorated by therapy targeting the C5-C5aR axis. - Antiphospholipid score is a novel risk factor for idiopathic osteonecrosis of the femoral head in patients with systemic lupus erythematosus.
Ryo Hisada; Masaru Kato; Naoki Ohnishi; Eri Sugawara; Yuichiro Fujieda; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Shinsuke Yasuda; Tatsuya Atsumi
Rheumatology (Oxford, England), 58, 4, 645, 649, 2019年04月01日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: Idiopathic osteonecrosis of the femoral head (ION) is a common complication of SLE associated with CS therapy. Although the pathogenesis of ION involves local bone ischaemia favoured by thrombophilia, the involvement of aPL in lupus ION remains to be elucidated. We have previously reported the aPL score (aPL-S) as a quantitative marker of aPL and the development of thrombotic events in autoimmune diseases. The aim of this study was to identify the impact of aPL on the development of ION using aPL-S. METHODS: This was a single-centre retrospective study comprising 88 consecutive SLE patients who underwent MRI of the hip joints from January 2000 to March 2017. Baseline characteristics, pharmacotherapy and total hip arthroplasty performed during follow-up were evaluated. RESULTS: The presence of ION was confirmed by MRI scan in 38 patients (43.1%). Male gender, positivity of any aPL, aPL-S, high aPL-S (≥30) and high dose of CS were identified as risk factors for ION by univariate analysis. Multivariate analysis revealed high aPL-S (odds ratio 5.12, 95% CI 1.18-29.79) and use of high-dose CS (odds ratio 10.25, 95% CI 3.00-48.38) as independent variables. Kaplan-Meier analysis showed that patients with high aPL-S received total hip arthroplasty more frequently than those without aPL (P = 0.010). CONCLUSIONS: We newly identified high aPL-S as an important risk factor for ION development in SLE, suggesting the involvement of aPL-induced coagulopathy in the pathophysiology of lupus ION. - Clinical profiles and risk assessment in patients with antiphospholipid antibodies.
Masaru Kato; Ryo Hisada; Tatsuya Atsumi
Expert review of clinical immunology, 15, 1, 73, 81, 2019年01月, [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia associated with the presence of persistent antiphospholipid antibodies (aPL). Owing to recent studies, not only APS patients but also incidentally-identified, asymptomatic aPL carriers are able to be stratified in terms of the risk of future thrombotic events, according to the variety and the titer of positive aPL tests and to the non-thrombotic, aPL-associated clinical manifestations. Areas covered: Here, we critically review (1) criteria manifestations of APS, (2) non-criteria manifestations of APS, (3) risk assessment in patients with APS and in aPL carriers, and (4) the potential role of primary thrombosis prophylaxis in aPL carriers. In addition, we discuss what we are currently able to do and what we need to do in the future for primary prophylaxis against a first thrombotic event. Expert commentary: We suggest a comprehensive algorithm to stratify thrombotic risk in aPL carriers, including criteria aPL, non-criteria aPL, their scoring systems, and non-criteria manifestations. However, further studies, particularly prospective randomized controlled trials, are highly warranted to establish an effective and tolerable treatment regimen for high risk aPL carriers. - Clinical significance of plasma presepsin levels in patients with systemic lupus erythematosus.
Shun Tanimura; Yuichiro Fujieda; Michihiro Kono; Yuhei Shibata; Ryo Hisada; Eri Sugawara; Hiroyuki Nakamura; Kazumasa Ohmura; Sanae Shimamura; Asako Mitani; Haruki Shida; Toshiyuki Watanabe; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Shinsuke Yasuda; Chikara Shimizu; Tatsuya Atsumi
Modern rheumatology, 28, 5, 865, 871, 2018年09月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVES: Presepsin (PSEP: soluble CD14 subtype) is produced from bacteria-stimulated monocytes or neutrophils, thus recognized as a biomarker of sepsis. Aberrant functions in monocyte or neutrophils are increasingly recognized in systemic lupus erythematosus (SLE). We investigated whether plasma PSEP reflects disease activity in patients with SLE. METHODS: This retrospective study comprised 35 patients with SLE and 72 with non-SLE autoimmune diseases who visited our facility during the period from August 2012 to September 2015. Plasma PSEP levels and laboratory data were compared between SLE and non-SLE. Clinical markers of SLE disease activity, including SLE disease activity index 2000 (SLEDAI-2K), serum complement concentrations and serum anti-ds-DNA antibodies were assessed in correlation with plasma PSEP levels. RESULTS: Plasma PSEP levels in SLE were higher than those in non-SLE. This phenomenon holds true when comparing SLE and non-SLE patients in the absence of infection (p = .0008). Plasma PSEP levels in SLE patients negatively correlated with C3 (r = -0.4454, p = .0430), CH50 (r = -0.4502, p = .0406) and positively with SLEDAI-2K (r = 0.4801, p = .0237). CONCLUSION: Elevated plasma PSEP levels were correlated with disease activity of SLE, suggesting inappropriate monocyte or neutrophil activation in the pathophysiology of SLE exacerbation. - 関節リウマチ(RA)患者におけるTNF阻害薬の治療反応性予測スコアリングシステムの作成
菅原 正成; 栗田 崇史; 大村 一将; 久田 諒; 藤枝 雄一郎; 清水 裕香; 深谷 進司; 神田 真聡; 浄土 智
日本リウマチ学会総会・学術集会プログラム・抄録集, 62回, 713, 713, (一社)日本リウマチ学会, 2018年03月, [査読有り]
日本語 - Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies
T. Watanabe; K. Oku; O. Amengual; R. Hisada; K. Ohmura; I. Nakagawa; H. Shida; T. Bohgaki; T. Horita; S. Yasuda; T. Atsumi
Lupus, 27, 2, 225, 234, SAGE Publications Ltd, 2018年02月01日, [査読有り]
英語, 研究論文(学術雑誌) - Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study
R. Hisada; M. Kato; E. Sugawara; Y. Fujieda; K. Oku; T. Bohgaki; O. Amengual; S. Yasuda; T. Atsumi
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 15, 9, 1782, 1787, 2017年09月, [査読有り]
英語, 研究論文(学術雑誌) - 高陽性的中率検査の組み合わせによる効率的な抗リン脂質抗体症候群のスクリーニングについて
中村 浩之; 奥 健志; 大西 直樹; 久田 諒; 大村 一将; 藤枝 雄一郎; 加藤 将; 坊垣 暁之; アメングアル・オルガ; 保田 晋助; 渥美 達也
日本血栓止血学会誌, 28, 2, 230, 230, (一社)日本血栓止血学会, 2017年04月, [査読有り]
日本語 - 抗リン脂質抗体症候群における末梢血リンパ球サブセットおよび一塩基多型(SNP)の解析
久田 諒; 加藤 将; 菅原 恵理; 中村 浩之; 大村 一将; 中川 久子; 藤枝 雄一郎; 奥 健志; 坊垣 暁之; アメングアル・オルガ; 堀田 哲也; 保田 晋助; 渥美 達也
日本血栓止血学会誌, 28, 2, 229, 229, (一社)日本血栓止血学会, 2017年04月, [査読有り]
日本語 - SLE・抗リン脂質抗体症候群 活動性ループス腎炎に対する中等量ステロイド併用ミコフェノール酸モフェチルによる寛解導入療法の有効性
河野 通大; 保田 晋助; 阿部 早和子; 大西 直樹; 土井 基嗣; 谷村 瞬; 久田 諒; 菅原 恵理; 中村 浩之; 大村 一将; 嶋村 抄苗; 清水 裕香; 藤枝 雄一郎; 加藤 将; 奥 健志; 坊垣 暁之; アメングアル・オルガ; 渥美 達也
日本リウマチ学会総会・学術集会プログラム・抄録集, 61回, 460, 460, (一社)日本リウマチ学会, 2017年03月, [査読有り]
日本語 - P1-19 抗リン脂質抗体症候群における末梢血リンパ球サブセット解析および抗体産生機序の解明
久田 諒; 加藤 将; 菅原 恵理; 藤枝 雄一郎; 奥 健志; 坊垣 暁之; Amengual Olga; 保田 晋助; 渥美 達也
日本臨床免疫学会会誌, 40, 4, 302c, 302c, 日本臨床免疫学会, 2017年
日本語,【背景/目的】抗リン脂質抗体症候群(APS)において抗リン脂質抗体(aPL)は病原性を有する自己抗体とされるが,その産生機序については不明な点が多い.今回,APS患者における末梢血リンパ球サブセットを行い,更に末梢血単核球細胞(PBMC)をex vivoの系で刺激しaPL産生能をもつ細胞の同定を試みるアプローチを行った.【方法】原発性抗リン脂質抗体症候群(PAPS)患者,全身性エリテマトーデス続発性抗リン脂質抗体症候群(SLE/APS)患者,健常者の3群について,リンパ球サブセット解析を行い比較した.次にCD20 microbeadsを用いてCD20陽性細胞を除去したAPS患者のPBMCを刺激・培養し,培養上清中のaPLをELISA法及びcell-based assayにより測定した.【結果】PAPS群18名,SLE/APS群8名,健常者群8名についてサブセット解析を行った.Pre-switched memory B cell(p = 0.030),post-switched memory B cell(p = 0.032)はPAPS群で健常者群と比べ有意に減少していた.また,一部のAPS患者のPBMC培養上清からaPL-IgG(ELISA),aPL-IgM(cell-based assay)が検出され,CD20陽性細胞を除去したPBMCの培養上清中からもaPL-IgG,aPL-IgMが検出された.【結論】PAPS患者においてpre-switched memory B cellとpost-switched memory B cellの減少が見られた.また,aPL産生にCD20陰性B細胞が寄与している可能性が示唆された.
- Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide.
Eri Sugawara; Masaru Kato; Ryo Hisada; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Internal medicine (Tokyo, Japan), 56, 4, 445, 448, 2017年, [国内誌]
英語, 研究論文(学術雑誌), Pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MTCD), in contrast to other types of PAH, may respond to immunosuppressive therapy. Most PAH cases with an immunosuppressant response were in the early stages of the disease (WHO functional class III or less). The present case was a 34-year-old woman with MCTD-associated PAH (WHO functional class IV) who was resistant to a combination of three vasodilators. Afterwards, she was treated with glucocorticoid and cyclophosphamide. This case suggested the potential benefit of immunosuppressants in patients with severe MCTD-associated PAH. - Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE.
Yuka Shimizu; Shinsuke Yasuda; Yuki Kako; Shin Nakagawa; Masatoshi Kanda; Ryo Hisada; Kazumasa Ohmura; Sanae Shimamura; Haruki Shida; Yuichiro Fujieda; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Ichiro Kusumi; Tatsuya Atsumi
Autoimmunity reviews, 15, 8, 786, 94, 2016年08月, [国際誌]
英語, 研究論文(学術雑誌), In patients with systemic lupus erythematosus (SLE), neuropsychiatric (NP) symptoms sometimes occur after administration of corticosteroids, making differential diagnosis between NPSLE and steroid-induced psychosis challenging for clinicians. The aim of this study was to clarify the characteristics of post-steroid NP disease (PSNP) in patients with SLE. Clinical courses of 146 patients with SLE and 162 with other systemic autoimmune diseases, all in the absence of NP manifestations on admission, were retrospectively analyzed. Forty-three NPSLE patients on admission (de novo NPSLE) were also investigated. All patients were consecutively recruited and treated with 40mg/day or more of prednisolone in Hokkaido University Hospital between April 2002 and March 2015. The prevalence of PSNP was strikingly higher in SLE patients than other systemic autoimmune diseases (24.7% vs. 7.4%, OR 4.09, 95% CI 2.04-8.22). As independent risk factors to develop PSNP in SLE patients, past history of mental disorder and the presence of antiphospholipid syndrome were identified using multiple logistic regression analysis. In patients with PSNP-SLE, mood disorder was significantly more frequent than in de novo NPSLE (47.2% vs. 20.9%, OR 3.38, 95% CI 1.26-9.04). Of PSNP-SLE patients, two-thirds were with one or more abnormal findings in cerebrospinal fluid, electroencephalogram, MRI or SPECT. Majority of our PSNP-SLE patients received intensified immunosuppressive treatments and experienced improvement in most cases. PSNP-SLE had better relapse-free survival than de novo NPSLE (p<0.05, log rank test). In conclusion, PSNP frequently occurred in patients with SLE and treated successfully with immunosuppressive therapy, indicating that NPSLE is likely to harbor patients with PSNP-SLE. - Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome.
Kenji Oku; Olga Amengual; Ryo Hisada; Kazumasa Ohmura; Ikuma Nakagawa; Toshiyuki Watanabe; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Rheumatology (Oxford, England), 55, 8, 1403, 11, 2016年08月, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: To investigate the prevalence and significance of the autoantibodies against complement component 1 q subcomponent (C1q) in patients with APS. METHODS: In all, 40 consecutive primary APS patients, 42 patients with non-SLE CTDs and 20 SLE patients negative for aPL were enrolled in this retrospective analysis. Refractory APS was defined as a clinical status of recurring thrombosis or pregnancy morbidity during adequate secondary prophylaxis. An ELISA was used to measure serum levels of anti-C1q antibodies and anaphylatoxins (C3a, C4a). RESULTS: Anti-C1q antibodies were found in 36% (15/42) and 2.5% (1/40) of primary APS patients and controls, respectively. Among primary APS patients, anti-C1q antibody titres were significantly correlated with serum C4a levels (P = 0.013). Neither the prevalence nor the titre of anti-C1q antibodies was associated with any specific clinical manifestations of APS, nor titres of aPL. Refractory APS patients (n = 10) had a higher prevalence of anti-C1q antibodies (9/10 vs 6/32, P = 0.01) than APS patients without recurrence (n = 32). CONCLUSION: Anti-C1q antibodies are associated with complement activation in APS and may contribute to the pathogenesis, particularly in refractory cases. - Markers of thrombotic events in autoimmune diseases: Comparison of Antiphospholipid Score (aPL-S) and Global Anti-phospholipid Syndrome Score (GAPSS)
Kenji Oku; Olga Amengual; Hiroyuki Nakamura; Ryo Hisada; Kazumasa Oomura; Masaru Mato; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 112, 129, 130, 2015年11月, [査読有り]
英語 - Reduction of HLA Class II Expression and Beta-2-Glycoprotein I Presentation By Fluvastatin in Vitro and in Vivo: Possible Mechanism of Statin-Induced-Deprocoagulation in the Antiphospholipid Syndrome
Toshiyuki Watanabe; Kenji Oku; Olga Amengual; Ryo Hisada; Kazumasa Ohmura; Haruki Shida; Yuka Shimizu; Masaru Kato; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Akihiro Ishizu; Hisashi Arase; Tatsuya Atsumi
ARTHRITIS & RHEUMATOLOGY, 67, 2015年10月, [査読有り]
英語 - 訂正記事
奥 健志; アメングアル オルガ; 久田 諒; 大村 一将; 中川 育麿; 渡邊 俊之; 坊垣 暁之; 堀田 哲也; 保田 晋助; 渥美 達也
日本臨床免疫学会会誌, 38, 5, 389, 389, 日本臨床免疫学会, 2015年
日本語, 奥 健志,オルガアメングアル,久田 諒,大村一将,中川育麿,渡邊俊之,坊垣暁之,堀田哲也,保田晋助,渥美達也:完全自動化測定器による抗リン脂質抗体測定の意義.
日本臨床免疫学会会誌.38(3): 157−163, 2015.
下記のとおり追記訂正いたします。
利益相反
当該論文はアイ・エル・ジャパン株式会社からの委託研究の結果である。
日本臨床免疫学会会誌編集員会 - [The function and the significance of full-automated tests for detecting antiphospholipid antibodies].
Kenji Oku; Olga Amengual; Ryo Hisada; Kazumasa Oomura; Ikuma Nakagawa; Toshiyuki Watanabe; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 38, 3, 157, 63, 2015年, [国内誌]
日本語, 研究論文(学術雑誌), Antiphospholipid antibodies (aPLs) are a group of heterogenous antibodies with immunological and functional variations that are detected in the sera of patients with antiphospholipid syndrome (APS). Detection of these antibodies in an efficient and accurate manner remains a significant issue. It requires numerous immunological and functional tests, burdening the laboratory departments, and as a consequence, not sufficiently performed in many cases. We retrospectively studied a total of 212 subjects with or without collagen diseases including APS that visited the outpatients of multiple institutions (department of internal medicine at Health Science University of Hokkaido, department of medicine II and department of gastroenterology at Hokkaido University Hospital). All the subjects were measured aPL (anticardio anticardiolipin antibody IgG/IgM, anti-β2-glycoprotein I antibody IgG/IgM) using a fully automated chemiluminescence analyzer and compared measurement results with those obtained using the conventional ELISA method. These methods were found to have similar diagnostic accuracy, with κ values exceeding 0.6. Of 61 APS patients 41 (67%) were positive for two or more tests: significantly higher than other disease such as systemic lupus erythematosus (3/37, 9%) or non-SLE collagen disease (1/53, 2%). The fully automated chemiluminescence analyzer, which can simultaneously measure multiple aPLs, was thus determined to be useful for diagnosing APS. - Markers of Thrombotic Events in Autoimmune Diseases: Comparison of Antiphospholipid Score (aPL-S) and Global Anti-Phospholipid Syndrome Score (GAPSS).
Kenji Oku; Olga Amengual; Ryo Hisada; Kazumasa Oomura; Ikuma Nakagawa; Toshiyuki Watanabe; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
ARTHRITIS & RHEUMATOLOGY, 66, S1251, S1252, 2014年10月, [査読有り]
英語 - Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis
Ikuma Nakagawa; Kenji Oku; Olga Amengual; Ryo Hisada; Eri Sugawara; Kazumasa Ohmura; Tomoko Fukui; Sanae Shimamura; Haruki Shida; Toshiyuki Watanabe; Yuka Shimizu; Michihito Kono; Takashi Kurita; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
ARTHRITIS & RHEUMATOLOGY, 66, S1, S1, 2014年10月, [査読有り]
英語 - The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies.
Toshiyuki Watanabe; Kenji Oku; Olga Amengual; Eri Sugawara; Ryo Hisada; Kazumasa Ohmura; Tomoko Fukui; Sanae Shimamura; Ikuma Nakagawa; Atsushi Noguchi; Haruki Shida; Michihito Kono; Yuka Shimizu; Takashi Kurita; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi
ARTHRITIS & RHEUMATOLOGY, 66, S1154, S1155, 2014年10月, [査読有り]
英語 - Giant cell arteritis.
Satoshi Jodo; Ryo Hisada
Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology, 36, 6, 459, 66, 2013年, [国内誌]
英語, 研究論文(学術雑誌), Giant cell arteritis (GCA) is a granulomatous arteritis and it occurs older (more than 50 years) individuals. As GCA frequently involves temporal artery, this disease had been called as temporal arteritis. However, except for the temporal artery, GCA affects branches of the carotid arteries, as well as aorta and its major branches preferentially. Thus, this arteritis is collectively called as GCA from the characteristic histological findings. We systematically introduce the clinical pictures of GCA in the first half of this article. Because affected arteries of GCA are different in each patient, some patients do not present with classical clinical features, such as headache and tenderness of temporal artery. Recently, there are several variant forms of GCA have been recognized. Certain subtypes demonstrate organ dysfunction, such as visual loss or peripheral neuropathy with minimal or absent classical and systemic manifestations. This form of GCA is referred to as occult GCA. On the other hand, other form of GCA presents with a systemic inflammatory syndrome in the absence of focal ischemic symptoms. This is referred to as silent or masked GCA. In the latter half of this article, we introduce two patients presenting with such atypical presentations. One could be diagnosed as occult GCA, and the other was diagnosed as silent GCA with large vessel type. GCA is a heterogenous disease with more than a single clinical picture. This article can provide considerations of the wide spectrum of presentation of this characteristic systemic arteritis.
- リウマチ性疾患の基礎研究1 経皮的耳介迷走神経刺激による関節リウマチ治療の新規バイオマーカー同定
藤枝 雄一郎; 中村 浩之; 工藤 友喜; 狩野 皓平; 久田 諒; 河野 通仁; 金子 祐子; 村上 正晃; 渥美 達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 70回, 642, 642, 2026年03月
(一社)日本リウマチ学会, 日本語 - 若年全身性エリテマトーデス患者における睡眠健康状態と精神神経症状との関連性:PLEASURE-Jコホートを用いた検討
吉村大; 吉村大; 藤枝雄一郎; 久田諒; 河野通仁; 磯島咲子; 一瀬邦弘; 岩田恭宜; 奥健志; 金子佳代子; 佐田憲映; 田中良哉; 藤尾圭志; 松下雅和; 宮前多佳子; 村島温子; 中島亜矢子; 渥美達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 69th, 2025年 - 膠原病患者のニューモシスチス肺炎における定量的CT画像を用いた予後予測
崎山広大; 久田諒; 加藤将; 菅原正成; 清水裕香; 河野通仁; 藤枝雄一郎; アメングアルオルガ; 渥美達也, 日本内科学会雑誌, 113, 2024年 - SARS-CoV-2ワクチン接種はホスファチジルセリン依存性抗プロトロンビン抗体の産生を亢進させうる
安田充孝; 藤枝雄一郎; 守谷悠; 久田諒; 河野通仁; 加藤将; AMENGUAL Olga; 安本篤史; 森下英理子; 浦野哲盟; 渥美達也, 日本血栓止血学会誌, 35, 2, 2024年 - 長期観察で血栓症発症を確認しえた産科的抗リン脂質抗体症候群4例の臨床像
井上雄太; 藤枝雄一郎; 安田充孝; 久田諒; 河野通仁; AMENGUAL Olga; 加藤将; 渥美達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 68th, 2024年 - リウマチ性疾患における分子標的療法の現在と未来-主に生物学的製剤を用いて-全身性硬化症(全身性強皮症)
久田諒; 加藤将, 月刊リウマチ科, 71, 6, 2024年 - 抗リン脂質抗体症候群患者における単球/HDLコレステロール比の上昇は血栓性イベント再発リスクを反映する
守谷悠; 久田諒; 河野通仁; 藤枝雄一郎; 加藤将; OLGA Amengual; 渥美達也, 日本臨床免疫学会総会プログラム・抄録集, 52nd, 2024年 - 全身性強皮症関連間質性肺疾患(SSc-ILD)に対するシクロホスファミド(IVCY)とニンテダニブ併用療法
沖庸太郎; 加藤将; 鎌田和郎; 久田諒; 河野通仁; 藤枝雄一郎; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 39th, 2024年 - ループス腎炎における寛解導入治療期間中の腎転帰の予測因子
鎌田和郎; 河野道仁; 竹山脩平; 久田諒; 藤枝雄一郎; 加藤将; アメングアル オルガ; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 39th, 2024年 - 呼吸機能検査と運動負荷心エコーを組合わせたPAHスクリーニング
鎌田和郎; 加藤将; 石坂傑; 久田諒; 河野通仁; 藤枝雄一郎; 佐藤隆博; 辻野一三; アメングアル オルガ; 渥美達也, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 9th (CD-ROM), 2024年 - PVOD/PCHに対してイマチニブを使用した5症例の検討
中村順一; 辻野一三; 辻野一三; 島秀起; 杉本絢子; 佐藤隆博; 佐藤隆博; 大平洋; 鈴木雅; 常田慧徳; 久田諒; 加藤将; 今野哲; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 8th, 2023年 - 変革期を迎えた肺高血圧症 次世代の病態理解,診断,治療とは?各種肺高血圧症の診断と治療 膠原病に合併する肺高血圧症の鑑別と治療
加藤将; 久田諒, 循環器ジャーナル, 71, 4, 2023年 - MR Vessel Wall ImagingはSLE患者において神経精神ループスの診断能を向上させる
垂水政人; 藤枝雄一郎; 久田諒; 河野通仁; 加藤将; アメングアルオルガ; 渥美達也, 日本臨床免疫学会総会プログラム・抄録集, 51st, 2023年 - Epstein-Barrウイルスの再活性化が原因と考えられたdifficult to treat rheumatoid arthritisの3例
井上雄太; 藤枝雄一郎; 宮本健一; 鎌田和郎; 沖庸太郎; 久田諒; 河野通仁; AMENGUAL Olga; 加藤将; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 38th, 2023年 - 多発仮性動脈瘤を契機に血管型Ehlers-Danlos症候群と診断された一例
吉村大; 久田諒; 垂水政人; 河野通仁; 藤枝雄一郎; 加藤将; アメングアル オルガ; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 自己免疫性肺胞蛋白症を合併した全身性エリテマトーデスの一例
鎌田和郎; 久田諒; 沖庸太郎; 小森卓; 崎山広大; 多田麻里亜; 守谷悠; 河野通仁; 藤枝雄一郎; 加藤将; AMENGUAL Olga; 今野哲; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 定量的CTによる異常肺容積値は全身性強皮症に伴う間質性肺疾患の予後を予測する
多田麻里亜; 加藤将; 崎山広大; 守谷悠; 安田充孝; 久田諒; 河野通仁; 藤枝雄一郎; アメングアル オルガ; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 筋に限局した小型血管炎の2例
守谷悠; 藤枝雄一郎; 多田麻里亜; 崎山広大; 安田充孝; 久田諒; 河野通仁; 加藤将; AMENGUAL Olga; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - SARS-CoV-2mRNAワクチン接種後の抗リン脂質抗体価の変化に関する検討
安田充孝; 藤枝雄一郎; 崎山広大; 多田麻里亜; 守谷悠; 久田諒; 河野通仁; 加藤将; AMENGUAL Olga; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 患者由来iPS細胞を用いた強皮症性肺動脈性肺高血圧症の病態解明
工藤友喜; 加藤将; 柴田悠平; 久田諒; 河野通仁; 藤枝雄一郎; アメングアル オルガ; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 肺静脈病変に特徴的な胸部CT所見を有する全身性強皮症患者の循環呼吸動態
守谷悠; 加藤将; 蜷川慶太; 久田諒; 河野通仁; 藤枝雄一郎; AMENGUAL Olga; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 全身性エリテマトーデスの維持期における寛解達成及び再燃予測因子に関する検討
竹山脩平; 河野通仁; 久田諒; 藤枝雄一郎; 加藤将; アメングアル オルガ; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 成人発症スティル病との鑑別を要した皮下脂肪織炎様T細胞リンパ腫の一例
加地紫苑; 多田麻里亜; 鎌田和郎; 沖庸太郎; 崎山広大; 安田充孝; 守谷悠; 久田諒; 河野通仁; 藤枝雄一郎; 加藤将; AMENGUAL Olga; 小野澤真弘; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 神経精神障害を有する全身性エリテマトーデスの診断におけるMR Vessel Wall Imagingの有用性の検討
垂水政人; 藤枝雄一郎; 久田諒; 河野通仁; 加藤将; アメングアル オルガ; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 単純X線検査で異常を示さない早期脊椎関節炎・関節リウマチの全身MRI所見
小住由衣; 麻生邦之; 加藤将; 久田諒; 河野通仁; 藤枝雄一郎; アメングアル オルガ; 神島保; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 関節リウマチ患者の魚の摂取量と分子標的治療の治療経過との関連
垂水政人; アメングアル オルガ; 安田充孝; 小住由衣; 竹山脩平; 吉村大; 久田諒; 河野通仁; 藤枝雄一郎; 加藤将; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 胸椎病変を認めたSAPHO症候群の1例
沖庸太郎; 久田諒; 鎌田和郎; 崎山広大; 多田麻里亜; 守谷遥; 河野通仁; 藤枝雄一郎; 加藤将; AMENGUAL Olga; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 37th, 2022年 - 全身性強皮症に対する自家末梢血幹細胞移植の長期成績
中村浩之; 保田晋助; 大西直樹; 谷村瞬; 久田諒; 藤枝雄一郎; 加藤将; 奥健志; 坊垣暁之; アメングアル オルガ; 渥美達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 62nd, 2018年 - HIGH RISK OF IDIOPATHIC OSTEONECROSIS IN SLE PATIENTS WITH HIGH ANTIPHOSPHOLIPID SCORE AND HYPERTRIGLYCERIDEMIA
R. Hisada; M. Kato; N. Ohnishi; M. Kono; S. Tanimura; E. Sugawara; H. Nakamura; K. Ohmura; S. Shimamura; Y. Fujieda; K. Oku; T. Bohgaki; O. Amengual; S. Yasuda; T. Atsumi, ANNALS OF THE RHEUMATIC DISEASES, 76, 598, 598, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - USEFULNESS OF SERUM HAPTOGLOBIN LEVELS AS A NOVEL MARKER FOR PULMONARY ARTERIAL HYPERTENSION COMPLICATED WITH CONNECTIVE TISSUE DISEASE
H. Nakamura; M. Kato; M. Kono; S. Tanimura; R. Hisada; E. Sugawara; K. Ohmura; S. Shimamura; Y. Fujieda; K. Oku; T. Bohgaki; O. Amengual; S. Yasuda; T. Atsumi, ANNALS OF THE RHEUMATIC DISEASES, 76, 624, 625, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - AUTOANTIBODY AGAINST COMPLEMENT COMPONENT 1Q SUBCOMPONENT IS ASSOCIATED WITH THE PATHOGENESIS OF RECURRENT PREGNANCY LOSS
K. Ohmura; K. Oku; T. Kitaori; M. Kono; S. Tanimura; E. Sugawara; R. Hisada; H. Nakamura; S. Shimamura; Y. Fujieda; M. Kato; T. Bohgaki; O. Amengual; S. Yasuda; M. Sugiura-Ogasawara; T. Atsumi, ANNALS OF THE RHEUMATIC DISEASES, 76, 1453, 1454, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - 抗リン脂質抗体症候群における末梢血リンパ球サブセットおよび一塩基多型(SNP)の解析
久田 諒; 加藤 将; 菅原 恵理; 中村 浩之; 大村 一将; 中川 久子; 藤枝 雄一郎; 奥 健志; 坊垣 暁之; アメングアル・オルガ; 堀田 哲也; 保田 晋助; 渥美 達也, 日本血栓止血学会誌, 28, 2, 229, 229, 2017年04月
(一社)日本血栓止血学会, 日本語 - H因子の低下による補体代替経路活性化が抗リン脂質抗体症候群の向血栓性に関与する
中村浩之; 奥健志; 大西直樹; 久田諒; 大村一将; 藤枝雄一郎; 加藤将; 坊垣暁之; アメングアル オルガ; 保田晋助; 渥美達也, 日本血栓止血学会誌, 28, 2, 2017年 - オートファジーは滑膜線維芽細胞においてビメンチンのシトルリン化を促進する
菅原恵理; 加藤将; 久田諒; 藤枝雄一郎; 奥健志; 坊垣暁之; アメングアル オルガ; 渥美達也, 日本臨床免疫学会会誌, 40, 4, 2017年 - Deviation of T and B Cell Subset and Its Association with Single Nucleotide Polymorphisms in Patients with Antiphospholipid Syndrome
Ryo Hisada; Masaru Kato; Hisako Nakagawa; Eri Sugawara; Masatoshi Kanda; Kazumasa Ohmura; Ikuma Nakagawa; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 68, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - Preventive Effect of Combined Treatment with Bisphosphonate and Vitamin D on Atherosclerosis in Patients with Systemic Lupus Erythematosus
Kazumasa Ohmura; Masaru Kato; Toshiyuki Watanabe; Ryo Hisada; Masatoshi Kanda; Sanae Shimamura; Ikuma Nakagawa; Yuka Shimizu; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 68, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - Anti-CCP Antibody Titers Decrease with Altered B-Cell Subpopulation in RA Patients Treated with Tocilizumab
Atsushi Noguchi; Shinsuke Yasuda; Ryo Hisada; Kazumasa Ohmura; Sanae Shimamura; Yuka Shimizu; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Olga Amengual; Tetsuya Horita; Miho Suzuki; Yoshihiro Matsumoto; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 68, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
Hiroyuki Nakamura; Kenji Oku; Ryo Hisada; Kazumasa Ohmura; Masaru Kato; Toshiyuki Bohgaki; Olga Amengual; Tetsuya Horita; Shinsuke Yasuda; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 68, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Kenji Oku; Uhei Shibata; Joana Batuca; Olga Amengual; Michihiro Kono; Hiroyuki Nakamura; Ryo Hisada; Kazumasa Ohmura; Masaru Kato; Toshiyuki Bohgaki; Shinsuke Yasuda; Jose Delgado Alves; Tatsuya Atsumi, ARTHRITIS & RHEUMATOLOGY, 68, 2016年10月
英語, 研究発表ペーパー・要旨(国際会議) - 全身性エリテマトーデス患者における動脈硬化進展と骨塩量との関連
大村 一将; 奥 健志; 渡邊 俊之; 谷村 瞬; 柴田 悠平; 河野 通大; 久田 諒; 菅原 恵理; 中村 浩之; 神田 真聡; 嶋村 抄苗; 清水 裕香; 加藤 将; 坊垣 暁之; 堀田 哲也; 保田 晋助; 渥美 達也, 日本臨床免疫学会会誌, 39, 4, 385, 385, 2016年08月
日本臨床免疫学会, 日本語 - ループス腎炎に対する寛解導入治療におけるミコフェノール酸モフェチルの短期的治療効果
河野 通大; 保田 晋助; 尾形 裕介; 阿部 早和子; 大西 直樹; 土井 基嗣; 谷村 瞬; 柴田 悠平; 中村 浩之; 菅原 恵理; 久田 諒; 神田 真聡; 大村 一将; 嶋村 抄苗; 清水 裕香; 加藤 将; 奥 健志; 坊垣 暁之; 堀田 哲也; 渥美 達也, 日本臨床免疫学会会誌, 39, 4, 386, 386, 2016年08月
日本臨床免疫学会, 日本語 - THROMBOCYTOPENIA IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A PARADOXICAL THROMBOTIC RISK FACTOR
R. Hisada; M. Kato; E. Sugawara; K. Ohmura; I. Nakagawa; K. Oku; T. Bohgaki; O. Amengual; T. Horita; S. Yasuda; T. Atsumi, ANNALS OF THE RHEUMATIC DISEASES, 75, 315, 315, 2016年06月
英語, 研究発表ペーパー・要旨(国際会議) - 抗リン脂質抗体陽性血小板減少症における血栓症発症リスク
久田 諒; 加藤 将; 大村 一将; 中川 育磨; 奥 健志; 坊垣 暁之; Amengual Olga; 堀田 哲也; 保田 晋助; 渥美 達也, 日本血栓止血学会誌, 27, 2, 222, 222, 2016年05月
(一社)日本血栓止血学会, 日本語 - リウマチ性疾患の合併症 膠原病性肺高血圧症における予後不良因子の検討
中村 浩之; Amengual Olga; 河野 通大; 谷村 瞬; 柴田 悠平; 久田 諒; 菅原 恵理; 服部 敏之; 大村 一将; 嶋村 抄苗; 野口 淳史; 志田 玄貴; 清水 裕香; 加藤 将; 奥 健志; 坊垣 暁之; 堀田 哲也; 保田 晋助; 渥美 達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 476, 476, 2016年03月
(一社)日本リウマチ学会, 日本語 - SLE・抗リン脂質抗体症候群 ループス腎炎 ループス腎炎の長期腎予後ならびに寛解導入治療に関する検討
河野 通大; 保田 晋助; 河野 通仁; 谷村 瞬; 柴田 悠平; 久田 諒; 菅原 恵理; 中村 浩之; 服部 敏之; 大村 一将; 嶋村 抄苗; 志田 玄貴; 清水 裕香; 加藤 将; 奥 健志; 坊垣 暁之; オルガ・アメングアル; 堀田 哲也; 渥美 達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 351, 351, 2016年03月
(一社)日本リウマチ学会, 日本語 - SLE・抗リン脂質抗体症候群 精神神経ループス 全身性エリテマトーデス患者における動脈硬化進展の予測因子の検討
大村 一将; 奥 健志; 渡邊 俊之; アメングアル・オルガ; 河野 通大; 谷村 瞬; 柴田 悠平; 中村 浩之; 久田 諒; 菅原 恵理; 服部 敏之; 嶋村 抄苗; 野口 淳史; 中川 育磨; 志田 玄貴; 清水 裕香; 加藤 将; 坊垣 暁之; 堀田 哲也; 保田 晋助; 渥美 達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 352, 352, 2016年03月
(一社)日本リウマチ学会, 日本語 - SLE・抗リン脂質抗体症候群 精神神経ループス 高用量ステロイド投与時に発症した全身性エリテマトーデスにおける精神神経症状の解析
清水 裕香; 保田 晋助; 神田 真聡; 河野 通大; 久田 諒; 大村 一将; 嶋村 抄苗; 志田 玄貴; 加藤 将; 奥 健志; 坊垣 暁之; アメングアル・オルガ; 堀田 哲也; 渥美 達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 353, 353, 2016年03月
(一社)日本リウマチ学会, 日本語 - SLE・抗リン脂質抗体症候群 SLE臨床 全身性エリテマトーデス患者における特発性大腿骨頭壊死症の背景因子の検討
久田 諒; 加藤 将; 河野 通大; 柴田 悠平; 谷村 瞬; 菅原 恵理; 大村 一将; 神田 真聡; 服部 敏之; 中村 浩之; 嶋村 抄苗; 中川 育磨; 志田 玄貴; 清水 裕香; 奥 健志; 坊垣 暁之; 堀田 哲也; 保田 晋助; 渥美 達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 60回, 416, 416, 2016年03月
(一社)日本リウマチ学会, 日本語 - 抗リン脂質抗体陽性全身性エリテマトーデス患者に対するHMG-CoA還元酵素阻害薬の血栓症抑制効果とその機序の解明
渡邊俊之; 渡邊俊之; 奥健志; アメングアル オルガ; 久田諒; 大村一将; 中川育磨; 志田玄貴; 清水裕香; 加藤将; 坊垣暁之; 堀田哲也; 保田晋助; 石津明洋; 荒瀬尚; 渥美達也, 日本血栓止血学会学術標準化委員会シンポジウム, 10th, 2016年 - 抗リン脂質抗体症候群の診断:抗リン脂質抗体スコアを中心に
奥健志; アメングアル オルガ; 中村浩之; 久田諒; 加藤将; 坊垣暁之; 堀田哲也; 保田晋助; 渥美達也, 日本血栓止血学会学術標準化委員会シンポジウム, 10th, 2016年 - 血栓症発症を予測する定量マーカーとしての抗リン脂質抗体 抗リン脂質抗体スコアとGlobal Anti-Phospholipid Syndrome Score(GAPSS)の比較
奥 健志; オルガ・アメングアル; 中村 浩之; 久田 諒; 大村 一将; 加藤 将; 坊垣 暁之; 堀田 哲也; 保田 晋助; 渥美 達也, Reproductive Immunology and Biology, 30, 1-2, 109, 109, 2015年11月
日本生殖免疫学会, 日本語 - 抗リン脂質抗体陽性血小板減少症における血栓症発症リスク
久田 諒; 加藤 将; 中川 育磨; 坊垣 暁之; 奥 健志; 堀田 哲也; 保田 晋助; 渥美 達也, 日本臨床免疫学会会誌, 38, 4, 352, 352, 2015年09月
【目的】抗リン脂質抗体(aPL)陽性血小板減少症と血栓症発症リスクとの関係を検討する.【方法】2004年1月~2006年12月に北海道大学病院膠原病外来を受診し,aPL(ループスアンチコアグラント,抗カルジオリピン抗体,抗β2グリコプロテインI抗体,ホスファチジルセリン依存性抗プロトロンビン抗体)を測定した連続670例のうち,全身性エリテマトーデスおよびフォローアップ1年以内の患者を除く337例を抽出した.aPLのプロファイル,血小板減少症(10万/μl以下)の合併,血栓症の有無を後ろ向きに解析した.【結果】aPL陽性群と陰性群では血小板減少症の頻度に有意差は見られなかった(16/138例(12%)vs 19/199例(10%),p = 0.58).aPL陽性者において,血小板減少群は非血小板減少群に比べて血栓症の発症が高率に見られ(11/16例(58%)vs 23/122例(19%),p < 0.001),特に動脈血栓症の発症が多かった(10/16例(63%)vs 18/122例(15%),p < 0.001).動脈血栓症の内訳は,血小板減少群では10例全例が脳梗塞であったのに対し,非血小板減少群では脳梗塞15例(83%),網膜動脈閉塞症2例(11%),心筋梗塞1例(6%)であった.また両群間のaPLプロファイルに有意差を認めなかった.一方aPL陰性者においては,血小板減少群と非血小板減少群で血栓症の発症率に有意差は見られなかった(4/20例(20%)vs 24/179例(13%),p = 0.49).【結論】aPL陽性血小板減少症は血栓症,特に動脈血栓症発症のリスクである., 日本臨床免疫学会, 日本語 - Predictive markers for thrombotic events in autoimmune diseases: comparison of antiphospholipid score (APL-S) and global anti-phospholipid syndrome score (GAPSS)
K. Oku; O. Amengual; R. Hisada; K. Oomura; Nakagawa, I; T. Watanabe; T. Bohgaki; T. Horita; S. Yasuda; T. Atsumi, JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13, 775, 775, 2015年06月
英語, 研究発表ペーパー・要旨(国際会議) - 抗好中球細胞質抗体関連血管炎における免疫抑制療法は血栓症発症を抑制する
中川 育磨; 奥 健志; 久田 諒; 菅原 恵理; 大村 一将; 服部 敏之; 嶋村 抄苗; 渡邊 敏之; 志田 玄貴; 清水 裕香; 坊垣 暁之; 堀田 哲也; 保田 晋助; 渥美 達也, 日本血栓止血学会誌, 26, 2, 182, 182, 2015年04月
(一社)日本血栓止血学会, 日本語 - 関節リウマチの治療 生物学的製剤(TNF阻害薬以外) 当科における関節リウマチに対するトシリズマブ休薬後の寛解維持予測因子の検討
野口 淳史; 保田 晋助; 河野 通仁; 菅原 恵理; 久田 諒; 大村 一将; 服部 敏之; 嶋村 抄苗; 中川 育磨; 志田 玄貴; 渡邊 俊之; 清水 裕香; 加藤 将; 奥 健志; 坊垣 暁之; 堀田 哲也; 渥美 達也, 日本リウマチ学会総会・学術集会プログラム・抄録集, 59回, 324, 324, 2015年03月
(一社)日本リウマチ学会, 日本語 - P3-006 フルバスタチンはHLA classIIによるβ-2グリコプロテインIの抗原提示を抑制する
渡邊 俊之; 堀田 哲也; 保田 晋助; 石津 明洋; 荒瀬 尚; 渥美 達也; 奥 健志; アメングアル オルガ; 久田 諒; 大村 一将; 志田 玄貴; 清水 裕香; 加藤 将; 坊垣 暁之, 日本臨床免疫学会会誌, 38, 4, 326b, 326b, 2015年
【背景】HLA-DRB1*07:01は抗リン脂質抗体症候群(APS)の疾患感受性遺伝子である.近年,我々はβ2-グリコプロテインI(β2GPI)/HLA class II複合体が抗β2GPI抗体の対応抗原であることを報告した.スタチン製剤はいくつかのAPSモデルで抗β2GPI抗体による向血栓細胞活性化を抑制し,血栓症抑制効果が期待されていたが,その機序は不明である.【目的】抗β2GPI抗体による血栓傾向に対するスタチン製剤の抑制的作用機序を解明する.【方法】不死化ヒト臍帯静脈血管内皮細胞(HUEhT-1)とヒト単球系細胞(THP-1)にβ2GPIとHLA-DRA*01:01/DRB1*07:01(HLA-DR7)の遺伝子を導入した後,フルバスタチンを添加し,細胞表面のHLA-DRとβ2GPIの発現およびヒトモノクローナル抗β2GPI依存性抗カルジオリピン抗体(EY2C9)の結合能を解析した.APS自然発症ラットであるenv-pXラットにフルバスタチンを投与し,β2GPI依存性抗カルジオリピン抗体(aCL)を測定した.【結果】HUEhT-1とTHP-1の両細胞表面において,β2GPIの発現およびEY2C9の結合はHLA-DR7発現細胞で亢進していた.フルバスタチンの添加により,HLA-DRとβ2GPIの細胞表面への発現およびEY2C9の結合は抑制され,メバロン酸によりフルバスタチンの作用は拮抗された.またフルバスタチン投与によりenv-pXラットのaCLは有意に低下した.【結語】スタチン製剤はHLA class IIの発現低下を介した自己抗原提示の抑制効果を示すため,APSへの治療効果が予想される., 日本臨床免疫学会, 日本語 - エタネルセプト治療中にANCA陽性MPAを発症した関節リウマチの1例
近藤桂一; 谷村瞬; 久田諒; 菅原基; 八反田文彦; 佐藤力; 藤枝雄一郎; 中垣整; 浄土智; 小川弥生, 北海道医学雑誌, 89, 1, 2014年 - 免疫グロブリン大量静注療法が奏功した,筋原性酵素の上昇を認めない多発性筋炎の1例
石田航平; 藤枝雄一郎; 谷村瞬; 近藤桂一; 久田諒; 菅原基; 八反田文彦; 佐藤力; 中垣整; 浄土智, 北海道医学雑誌, 89, 1, 2014年 - 成人発症スティル病(adult-onset Still’s disease)にDICを合併した1例
八反田文彦; 近藤桂一; 谷村瞬; 久田諒; 菅原基; 佐藤力; 藤枝雄一郎; 中垣整; 浄土智, 北海道医学雑誌, 89, 1, 2014年 - 広範な難治性神経病変を主症状とした全身性エリテマトーデスの1例
安田尚史; 久田諒; 菅原恵理; 大村一将; 服部敏之; 中川育磨; 野口淳史; 嶋村抄苗; 志田玄貴; 渡邊俊之; 清水裕香; 坊垣暁之; 奥健志; 堀田哲也; 保田晋助; 渥美達也, 日本臨床リウマチ学会プログラム・抄録集, 29th, 2014年 - ループス肺炎を合併したSLE患者の1例
谷村瞬; 近藤桂一; 久田諒; 菅原基; 八反田文彦; 佐藤力; 藤枝雄一郎; 中垣整; 浄土智, 日本臨床リウマチ学会プログラム・抄録集, 28th, 2013年 - 原発性シェーグレン症候群に微小変化型ネフローゼ症候群を合併した一例
近藤桂一; 服部敏之; 谷村瞬; 久田諒; 菅原基; 佐藤力; 大友耕太郎; 中垣整; 小川弥生; 八反田文彦; 藤枝雄一郎; 浄土智, 日本臨床リウマチ学会プログラム・抄録集, 28th, 2013年 - アバタセプト初回投与後に,水痘帯状疱疹ウイルスによる中枢神経病変を発症した関節リウマチの一例
八反田文彦; 近藤桂一; 谷村瞬; 久田諒; 菅原基; 佐藤力; 藤枝雄一郎; 浄土智, 日本臨床リウマチ学会プログラム・抄録集, 28th, 2013年
- 基本医学研究, 2024年, 修士課程, 医学院
- 基本医学総論, 2024年, 修士課程, 医学院
- 基本医学研究, 2024年, 修士課程, 医学院
- 基本医学総論, 2024年, 修士課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- 医学総論, 2024年, 博士後期課程, 医学院
- 基盤医学研究, 2024年, 博士後期課程, 医学院
- 臨床医学研究, 2024年, 博士後期課程, 医学院
- 成人健康障害論Ⅰ, 2024年, 学士課程, 医学部
- 成人健康障害論Ⅱ, 2024年, 学士課程, 医学部
- EGR-1を標的とした抗リン脂質抗体症候群における新規治療戦略の確立
科学研究費助成事業
2025年04月01日 - 2028年03月31日
久田 諒
日本学術振興会, 若手研究, 北海道大学, 25K19605 - 抗リン脂質抗体症候群における新規治療標的の同定
科学研究費助成事業
2023年04月01日 - 2025年03月31日
久田 諒
本研究は抗リン脂質抗体症候群の責任抗体と考えられている、抗リン脂質抗体(aPL)による単球活性化において、oxLDLの細胞内取り込みが重要な役割を果たしていると考え、その詳細な機序をすることを目的としている。当該年度の実験において、まずヒト単球の細胞株(THP-1)を用いて、フォスファチジルセリン依存性抗プロトロンビン抗体 aPS/PTをin vitroで添加し、組織因子の発現が亢進する条件の最適化を行った。その結果、最も組織因子を発現しやすいaPLの濃度と培養時間の設定を確立した。さらに、aPS/PTを添加したTHP-1において細胞内代謝を測定した所、glycolysisの増加が見られており、細胞内代謝の関連が示唆された。他の抗リン脂質抗体についてもハイブリドーマから精製を行い、研究の進展が得られた。
現在、oxLDLの細胞内取り込みによる単球活性化の促進の条件検討を行っており、oxLDLの諒や細胞数、培養時間の最適化を行っており、研究の目的を達成すべく測定を進めている。また、マウス単球の細胞株やヒトの全血から分離したプライマリ単球を用いた場合に同様の結果が得られるかについても併せて研究を進めている。これらの研究を通じて、oxLDLの細胞内取り込みにより生じる細胞内代謝の変動について検討し、新規治療法開発につなげることを目指している。更 にin vitroで成果が得られればマウスモデルを用いた研究を行う予定であり、あわせて研究計画を進めていく。
日本学術振興会, 若手研究, 北海道大学, 23K15334 - 細胞内代謝を標的とした抗リン脂質抗体症候群の新規治療開発
科学研究費助成事業
2022年08月31日 - 2024年03月31日
久田 諒
抗リン脂質抗体(aPL)による単球活性化の新たな機序として、細胞内代謝に着目した。ヒト単球の細胞株を用いて、フォスファチジルセリン依存性抗プロトロンビン抗体 aPS/PTをin vitroで添加し、seahorse analyzerを用いて細胞内代謝について測定した所、有意に亢進する代謝経路を見出した。機能解析のため、当該の代謝経路を阻害する薬剤を用いて、単球活性化マーカーである組織因子の発現を測定した所、濃度依存性に組織因子の発現を抑制することが明らかとなった。 更に、網羅的メタボローム解析を施行した所、上記と同様の代謝経路の亢進が見られた他、別の代謝経路の有意な亢進についても確認された。
日本学術振興会, 研究活動スタート支援, 北海道大学, 22K20752
